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ABSTRACT 
 
The Role of Apical Membrane Antigen-1 in Erythrocyte Invasion 
by the Zoonotic Apicomplexan Babesia microti. (August 2008) 
Issa Baradji, B.S., Institut Polytechnique Rurale de Katibougou, Mali; 
M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Patricia J. Holman 
 
Babesia microti is a tickborne hemoprotozoan parasite that causes the disease 
babesiosis in humans. Babesia microti Apical Membrane Antigen-1 (AMA-1) is a 
micronemal protein suspected to play a role in erythrocyte invasion. To investigate 
interaction between AMA-1 and the host cell, the ectodomain region of the B. microti 
ama-1 gene was cloned into an expression vector, expressed as a histidine-tagged fusion 
protein, and used to probe red blood cell membrane proteins in far Western blot assays.   
The B. microti ama-1 ectodomain, which excludes the signal peptide and the 
transmembrane region of the open reading frame, was amplified from a cloned gene 
sequence. The AMA-1 ectodomain is a membrane bound polypeptide that extends into 
the extracellular space and is most likely to interact or initiate interaction with the host 
red blood cell surface receptor(s). The amplicon was ligated into a protein expression 
vector to produce a 58.1 kDa recombinant His-tagged fusion protein, which was 
confirmed by Western blot analysis.  
  
  iv 
The recombinant B. microti AMA-1 fusion protein was enriched on nickel 
affinity columns and then used to probe mouse, human and horse red blood cell 
membrane proteins in far Western blot assays. Babesia microti AMA-1 consistently 
reacted strongly with a protein migrating at 49 kDa. A similar reaction occurred between 
the B. microti AMA-1 and horse red blood cell membrane proteins, suggesting that 
similar interacting proteins of this size are shared by red blood cells from the three 
species.  
The B. microti AMA-1 may bind to red blood cell membrane sialic-acid groups, 
as shown for other Babesia spp. This may explain the signal at the 49 kDa position 
observed between B. microti AMA-1 and red blood cell membrane proteins from three 
different species. Further studies may determine if the binding epitopes of the red blood 
cell binding partner at this position vary and contribute to the specificity of each parasite 
AMA-1 for their respective host cells.  
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     CHAPTER I 
                                                INTRODUCTION 
 
 
Babesia microti is a blood parasite that is transmitted by the tick Ixodes 
scapularis and is the most common cause of human babesiosis in the United States 
(Perry et al., 1977; Dammin et al., 1981; Piesman and Spielman, 1982). There is no 
reliable diagnostic test available today to detect infection prior to the clinical 
manifestations of the disease, there are no safe and effective drugs for treatment, and 
there is no vaccine to prevent transmission (Homer et al., 2000; Krause, 2003; Gelfand 
and Vannier, 2005). 
Proteins from the apical complex of apicomplexan parasites have been shown to 
mediate invasion of the host cell by these parasites (Dubremetz et al., 1998; Hodder et 
al., 2001; Yokoyama et al., 2006). These proteins are released from organelles of the 
apical complex and have been shown to play a critical role in parasite entry, 
internalization, and multiplication in the host cell.  
Apical membrane antigen-1 (AMA-1) is one of these proteins and is secreted 
from the micronemes. The characteristic features of AMA-1, such as a short 
transmembrane domain near the C-terminus, a predicted short cytoplasmic C-terminal 
sequence, and an extracellular domain containing 14 cysteine residues, are typically 
conserved in the amino acid sequence of the protein for all of the Apicomplexans studied  
 
This dissertation follows the formatting style of the Journal of Parasitology. 
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to date. This conservation indicates that this ligand plays an essential role in parasite 
functions (Triglia et al., 2000; Yokoyama et al., 2006).  Antibodies to AMA-1 have been 
shown in Plasmodium falciparum and in Babesia bovis to inhibit host erythrocytes 
invasion by these parasites (Hooder et al., 2001; Mosqueda et al., 2002; Gaur et al., 
2004; Silvie et al., 2004).  
Host cell receptors involved in interacting with AMA-1 have also been 
documented (Pasvol et al., 1982; Perkins, 1984; Zintl et al., 2002; Gaffar et al., 2003; 
Lobo, 2005). Glycophorin receptors on host erythrocytes have been shown to interact 
with the merozoites during invasion (Gaur et al., 2004). For instance, B. bovis 
merozoites were shown to invade human, ovine, equine, porcine, and caprine 
erythrocytes by a sialic acid-dependent mechanism (Gaffar et al., 2003). In addition, 
Babesia divergens and P. falciparum were shown to use common receptors, 
glycophorins A and B, to invade the human red blood cell (Pasvol et al., 1982; Lobo, 
2005). Treatment of bovine and non-bovine erythrocytes with neuraminidase decreased 
their susceptibility to invasion by B. divergens, which implicates sialic-acid as an 
important erythrocyte receptor for babesial invasion (Zintl et al., 2002). 
Babesia microti AMA-1, as demonstrated in other apicomplexans, is thought to 
play a role in erythrocyte invasion by this parasite. In this study, interaction of the 
BmAMA-1 ectodomain ligand with the host erythrocytes is explored using bioactivity 
assays, which include far Western blot analysis, immunoflurescent sntibody test, and 
immunocapture assays. 
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The objective of this study was to construct an expression plasmid containing the 
B. microti ama-1 ectodomain in order to produce recombinant protein that was used in 
downstream applications. Specific primers designed from the ectodomain portion of 
B. microti ama-1 were used to amplify this portion from the full B. microti ama-1 gene 
sequence (Fig. 1) by the polymerase chain reaction. The amplicon was purified and then 
ligated into an expression plasmid. The plasmid was sequenced to confirm the presence 
of the B. microti ama-1 ectodomain gene insert, as well as to confirm its orientation, and 
to determine if the sequence was in frame with the histidine tag. The choice of the 
ectodomain was important because this portion of the membrane bound polypeptide 
presumably extends into the extracellular space and likely interacts or initiates 
interaction with the host erythrocyte surface receptors.  
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CHAPTER II 
 
LITERATURE REVIEW 
 
 
Babesiosis is caused by hemoprotozoan parasites of the genus Babesia, which 
belong to the phylum Apicomplexa. Apicomplexans are obligate intracellular parasites 
that cause important parasitic diseases of humans and animals including malaria, 
babesiosis, coccidiosis, and toxoplasmosis (Mahoney, 1977; Homer et al., 2000). More 
than 100 Babesia species have been reported, but only a few have been identified as 
causing human infections (Purnell, 1981; Brocklesby, 1979; Gorenflot, 1998; Zintl et al., 
2003; Holman, Spencer, Droleskey et al., 2005; Holman, Spencer, Telford III, et al., 
2005). However, these parasites infect a wide variety of wild and domestic animals, and 
together are responsible for enormous economic losses to the livestock industry 
worldwide (McCosker, 1981; Kuttler, 1988; Taboada and Merchant, 1991).   
Babesia are tick-transmitted intraerythrocytic protozoan parasites (Herwaldt et 
al., 1996; Kjemtrup. and Conrad, 2000; Beattie et al., 2002). Transmission does occur 
through blood transfusion, organ transplant, or via vertical transmission from mother to 
newborn (Herwaldt et al., 1997; Kjemtrup and Conrad, 2000). Babesiosis is caused by 
any one of many Babesia species, which infect a wide variety of vertebrate hosts, 
including domestic and wild animals, as well as man (Mahoney, 1977; McCosker, 1981; 
Taboada.and Merchant, 1991; Telford et al., 1993).  
In the United States, human babesiosis is considered an emerging infectious 
disease (Kjemtrup and Conrad, 2000; Krause, 2002). Babesia microti is the agent most 
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frequently identified as causing human babesiosis, which occurs mainly in the 
Northeastern and Midwestern regions of the U.S. (Gray et al., 2002). Although 
infections are often subclinical, severe disease is seen in immunosuppressed individuals 
(Homer et al., 2000; Kjemtrup and Conrad, 2000; Krause, 2002). Human babesiosis 
caused by B. microti first was described from sites along the Northeastern United States, 
and later from Minnesota and Wisconsin (Perry et al., 1977; Dammin et al., 1981; 
Piesman and Spielman, 1982). Babesia microti is transmitted by the deer tick, Ixodes 
scapularis (Kjemtrup and Conrad, 2000; Krause, 2002). Its most common vertebrate 
reservoir is the white-footed mouse (Peromyscus leucopus) (Borggraefe et al., 2006; 
Gray et al., 2002). Humans enter the cycle when bitten by infected ticks or by transfer of 
infected blood to an immunocompromised individual. The Babesia-infected tick 
introduces sporozoites into the human host during a blood meal. The sporozoites enter 
erythrocytes and undergo asexual replication. The parasites at this stage are referred to 
as piroplasms due to their pear-shaped appearance when within the infected host cells 
(Suarez et al., 1991; Kjemtrup and Conrad, 2000). 
Multiplication of the blood stage parasites is responsible for the clinical 
manifestations of the disease (Gorenflot et al., 1998; Kjemptrup and Conrad, 2000). 
Humans are dead-end hosts and there is little or no subsequent transmission from ticks 
feeding on infected persons. But, human-to-human transmission is well documented and 
occurs through blood transfusions or organ transplantations (Herwaldt et al., 1996; 
Beattie et al., 2002).  
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Recently, worldwide interest in human babesiosis has increased as a result of 
human cases caused by new species distinct from B. microti and B. divergens European 
isolate (Herwaldt et al., 1996; Beattie et al., 2002; Kjemtrup et al., 2002;  Holman, 
Spencer, Telford III et al., 2005; Holman, 2006). In Europe, human babesiosis is rare but 
often severe. On the basis of morphology and antigen reactivity, most cases have been 
attributed to the cattle pathogen B. divergens. However, some of these cases may have 
been due to a closely related organism called the European Strain (Herwaldt et al., 
2003).  
Symptoms in human babesiosis range from a silent infection to severe malaria-
like disease which often results in the death of the infected host. Various determinants 
such as age, immune status of the infected host and coinfection with other pathogens 
appear to play a role in the severity of the disease manifestations (Brocklesby, 1979; 
Mahoney, 1979; Beattie et al., 2002; Krause, 2002; Krause, 2003).  
Infections caused by B. microti in Europe may be underdiagnosed. Babesia 
microti has been detected in I. ricinus, the tick that transmits B. divergens to cattle. This 
tick has been collected in various regions in Switzerland (Gray et al.,2002; Foppa et al., 
2002)  and in Poland as well (Karbowiak, 2004). Ixodes ricinus also is an efficient vector 
for B. microti, which indicates that incidence of this parasite in Europe may be 
underestimated (Duh et al., 2005; Meer-Scherrer et al., 2004). Serum from residents in 
Germany and Switzerland react to B. microti antigen (Hunfeld et al., 2002; Foppa et al., 
2002) indicating active or resolved infection with B. microti. In spite of all these 
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findings, the incrimination of B. microti in human illness in Europe is fairly recent (Duh 
et al., 2001; Foppa et al., 2002; Gray et al., 2002; Duh et al., 2005). 
DISEASE SYMPTOMS AND DIAGNOSIS 
Babesiosis is characterized by fever, anemia, icterus, and hemoglobinuria 
(Brocklesby, 1979; Krause, 2003). These symptoms are mainly due to the continuous 
cyclic asexual multiplication of the parasites in the host erythrocytes and the rupturing of 
the latter to invade new erythrocytes (Krause 2003). The severity of babesiosis is 
associated with this asexual reproduction, which leads to high parasitaemia, erythrolysis, 
anemia, and malaise in the infected animals (Taboada and Merchant, 1991; Herwaldt et 
al., 1996; Beattie et al., 2002; Krause, 2003). 
The diagnosis of babesiosis is based on the above cited symptoms and the 
observation of the parasites in stained blood smears (Fig. 1) (Kjemtrup and Conrad, 
2000; Krause, 2003). Parasite presence also can be confirmed by using diagnositc DNA 
probes to target parasite antigen in blood of infected hosts. The indirect fluorescent  
 
 
Figure 1. Babesia microti in mouse blood. 
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antibody test (IFAT) mainly is used for diagnosis of B. microti infection and has been 
specifically recommended for detecting the presence of IgG antibodies to B. microti 
(Taboada and Merchant, 1991; Brasseur et al., 1998). Additional tests include the 
enzyme-linked immunosorbent assay (ELISA), and Polymerase Chain Reaction (PCR) 
(Homer et al., 2000; Krause, 2003; Gelfand and Vannier, 2005). Antibodies to Babesia 
can be detected by IFAT and ELISA prior to the identification of the parasites in stained 
blood smears (Telford et al., 1993; Krause, 2003), but these assays cannot distinguish 
between active and resolved infections. PCR, a sensitive DNA detection test, detects 
early infection of the parasite before the development of detectable antibody, but does 
not provide information on the level of parasitemia (Homer et al., 2000; Krause, 2003; 
Gelfand and Vannier, 2005). However, real-time PCR allows detection of the increase in 
the amount of DNA as it is amplified and results using this assay correlated well with 
microscopic results (Swan et al., 2005).  
CONTROL OF BABESIOSIS 
In the United States, control of zoonotic babesial infections includes the use of 
acaricides, destruction of the tick habitat, and removal of animal reservoirs (Kuttler, 
1988; Kjemtrup and Conrad, 2000; Krause 2002). Such measures are not used in Europe 
because of the low incidence of the infection. But, measures should be taken to avoid 
exposure to areas where zoonotic babesiosis is endemic, such as simple avoidance to 
habitat modification, use of tick repellents before entering a tick-infested area, thorough 
examination of skin after exposure, daily self-examination for persons engaged in 
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outdoor activities in endemic areas and examination of pets for ticks (Dewaal, 2000; 
Kjemtrup and Conrad, 2000; Krause, 2003).  
Early treatment of babesial infections in humans, with well-recognized 
antimalarial drugs such as chloroquine, quinine, mefloquine and pyrimethamine, and 
pentamidine are not successful (Raoult et al., 1987; Brasseur et al., 1996; Denes et al., 
1999; Krause, 2003). Although chloroquine therapy improves symptoms in some 
patients infected with B. microti, the parasitemias appear to be maintained (Krause, 
2003). Berenil (diminazene aceturate), an antitrypanosomal compound known to be 
effective in veterinary cases, failed to cure a patient with a severe B. divergens infection 
(Raoult et al., 1987; Brasseur et al., 1996; Brasseur et al., 1998). In general, drug 
treatment of human babesiosis has failed because of the difficulty in clearing the 
parasite, and also the toxicity of the therapeutic procedures is problematic (Raoult et al., 
1987; Brasseur et al., 1996). Today, the recommended treatment of human babesiosis 
consists of a massive blood exchange transfusion followed by administration of 
intravenous clindamycin and oral quinine together (Brasseur et al., 1996; Denes et al., 
1999; Krause, 2003). The efficiency of clindamycin and quinine in clearing the parasite 
has been shown by in vitro experiments, yet in vivo experiments have the risk of 
increased parasitemia, consequent hemolysis, and renal damage (Brasseur et al., 1996; 
Brasseur et al,. 1998). Atovaquone is registered for use in humans and has been shown 
to clear B. divergens in human erythrocytes in vitro (Brasseur et al., 1998; Krause, 
2003). The drug was reported to be effective in vivo when used daily at low doses in a 
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gerbil model (Krause, 2003) and has been suggested for prevention in 
immunosuppressed individuals when exposed to human babesiosis (Krause, 2003).  
HOST CELL INVASION PROCESS IN APICOMPLEXANS 
 
Studies have shown that interactions between merozoites and host erythrocytes 
during the asexual growth cycle of Babesia are mediated by adhesive interactions of 
several parasite ligands and target receptors on host eryhtrocytes (Dubremetz et al.,1998; 
Zint et al., 2002; Yokoyama et al., 2006). During the invasion process, several surface-
coating molecules of merozoites might be involved in the initial attachment and entry of 
the parasite of the erythrocytes. Many proteins secreted from apical organelles (rhoptry, 
micronemes, and dense granules) have been identified as playing a role in erythrocyte 
penetration or internalization (Dubremetz et al., 1998). Studies have been carried out to 
identify interacting molecules in merozoite invasion of erythrocytes (Igarashi et al., 
1988; Gaffar et al., 2003; Yokoyama et al., 2006). The detailed molecular interactions 
between merozoites and receptors on host erythrocytes remain incompletely understood 
(Dvorak et al., 1975; Jack and Ward, 1981; Dubremetz et al., 1998). This lack of detailed 
knowledge of interacting molecules has hindered the development of a good vaccine and 
therapeutic drugs for babesial infections (Thomas et al., 1984; Yokoyama et al., 2006). 
The erythrocytes invasion process of B. microti, like many apicomplexans is 
thought to mimic that of  Plasmodium falciparum and is mediated by an apical complex  
located at the anterior end of the parasite (Dvorak et al., 1975; Mota et al., 2002; Gaur et 
al., 2004). Secreted proteins from the apical complex (rhoptries and micronemes, dense 
granules) are thought to play a central role in the sequence of events leading to cell 
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invasion by apicomplexan parasites (Taylor et al., 1990; Gaffar et al., 2004; Yokoyama 
et al. 2006).  
HOST CELL RECEPTORS INVOLVED IN INVASION BY APICOMPLEXANS  
Many studies have documented the nature of the erythrocyte receptors involved 
in invasion by the Apicomplexan parasites (Gaffar et al., 2004; Yokoyama et al. 2006).  
Sialic acid residues, protease-sensitive proteins, or sulphated glycosaminoglycans 
located on the surface of the erythrocytes have been identified as the host erythrocytes 
receptors for babesial invasion (Igarashi et al., 1988; Dubremetz et al.,1998; Gaffar et 
al., 2003; Yokoyama et al., 2006). Sialic acid residues on bovine erythrocytes have been 
implicated to function as the receptors for B. bovis, B. bigemina, and B. divergens (Zintl 
et al., 2002; Gaffar et al., 2003). Pretreatment of the bovine erythrocytes with 
neuraminidase significantly decreases invasion by the parasite. In addition, B. bovis and 
B. divergens   invade human and other animal erythrocytes in a sialic acid-dependent 
mechanism (Zintl et al., 2002).  
PARASITE LIGANDS INVOLVED IN INVASION OF HOST CELL  
Members of the apicomplexa infect different hosts and cell types, but they have 
similar host cell invasion processes. Unlike Plasmodium parasites, which require 
hepatocytes invasion and multiplication prior to the erythrocytic stage, sporozoites of 
Babesia parasites can directly invade the host erythrocytes and undergo an asexual 
growth cycle in the merozoite stage (Gelfand and Vannier, 2005). Since Rhoptry 
Associated Proteins 1 (RAP-1), Babesia bovis Apical membrane Antigen 1 ( BbAMA-
1), and Babesia bovis Thrombospondin Anonymous Protein (BbTRAP) are all detectable 
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in the supernatant of a B. bovis culture, these proteins seem to function as secretory 
proteins during erythrocyte invasion by merozoites (Gaffar et al., 2004). 
Although many proteins are known to play an important role in invasion, their 
functional characteristics remain unclear. A complete understanding of the molecular 
interactions involved in the invasion process is crucial in the design of therapeutics and 
vaccines to counter these diseases (Gaur et al., 2004).  
It is well known in malaria that the plasmodium invasion process begins by 
reversible attachment, followed by reorientation of the merozoite, which brings the 
apical end of the parasite in contact with the plasma membrane of the erythrocyte 
(Dvorak et al., 1975; Jack and Ward, 1981; Mota and Rodriguez, 2002; Gaur et al., 
2004). A tight junction is formed through which the parasite invades the red blood cell. 
From the first attachment until completion of the invasion process the parasite secretes 
proteins from apical organelles into the merozoite membrane and into the environment. 
The process is completed when the parasite is inside the erythrocytes (Dvorak et al., 
1975; Jack and Ward, 1981; Gaur et al., 2004). The role of these proteins in the entry, 
internalization and multiplication of the parasites in the host cell yet needs to be 
determined (Jack and Ward, 1981; Dubremetz et al., 1998; Gaffar et al., 2004; 
Yokoyama et al., 2006). Proteins released from Babesia spp. apical end are often soluble 
and secreted by the parasite during host erythrocyte invasion (Perkins, 1984; Dubremetz 
et al., 1998; Yokoyama et al., 2006). 
The roles played by parasites ligands Apical Membrane Antigen-1 (AMA-1), 
Rhoptries Associated proteins (RAP), and Thrombospondin-Related Anonymous Protein 
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(TRAP) during host cell invasion have been the focus of many scientists (Collins et al., 
1994; Anders et al; 1998; Dubremetz et al., 1998; Triglia et al., 2000; Adrian et al., 
2000; Soren et al., 2000; Hodder et al., 2001; Mosqueda et al., 2002; Gaur et al., 2004; 
Silvie et al., 2004; Yokoyama et al., 2006). Ligands from apicomplexan parasites are 
speculated to mediate the host cell invasion by these parasites. The role of these ligands 
in host cell invasion is still not well understood in spite of all the data collected so far 
supporting this view (Hodder et al., 2001; Triglia et al., 2000; Yokoyama et al., 2006).  
AMA-1 is a micronemal protein secreted to the surface of merozoites of 
Plasmodium species and Toxoplasma gondii tachyzoites in order to fulfill an essential 
but uncharacterized function in host cell invasion (Triglia et al., 2000; Mota and 
Rodriguez, 2002; Gaur et al., 2004; Yokoyama et al., 2006). Although the biological 
function of AMA-1 is unknown, the subcellular localization, stage-specific expression, 
and secretion during host cell invasion suggest that it is involved in merozoite invasion 
(Triglia et al., 2000; Yokoyama et al., 2006). An AMA-1 homologue is present in all 
Plasmodium species studied to date and in T. gondii, which supports the suggestion that 
this protein is involved in an essential function (Triglia et al., 2000; Hodder et al., 2001; 
Silvie et al., 2004). That it functions in erythrocyte invasion is demonstrated by the 
ability of anti-AMA-1 IgG to inhibit parasite invasion (Collins et al., 1994; Anders et al., 
1998; Adrian et al., 2000; Silvie et al., 2004).  Also, a strong correlation exists between 
protection and Plasmodium AMA-1 (Thomas et al., 1984; Collins et al., 1994). AMA-1 
homologs have been found in many apicomplexans parasites and the characteristic 
features of this parasite ligand, such as a transmembrane domain near the C terminus, a 
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predicted short cytoplasmic C-terminal sequence, and an extracellular domain containing 
14 cysteine residues, are typically conserved in the amino acid sequence (Adrian et al., 
2000; Gaffar et al., 2004; Gaur et al., 2004; Zhou et al., 2006). Babesia bovis AMA-1, 
like the Plasmodium spp. AMA-1, is implicated in erythrocyte invasion by the parasite. 
This is evidenced by the inhibition of invasion by parasites into bovine erythrocytes 
using anti-AMA-1 peptide specific antibodies to P. falciparum AMA-1 (Gaffar et al., 
2004; Yokoyama et al., 2006). The B. bovis AMA-1, with molecular weight of 82 kDa, 
was localized to the apical half of merozoites with peptide specific antibodies (Gaffar et 
al., 2004).  
Protective immunity is induced in squirrel monkeys by recombinant AMA-1 
from Plasmodium fragile (Collins et al., 1994), whereas mice are protected against 
infection by Plasmodium chabaudi after immunization with recombinant AMA-1 
(Anders et al., 1998). The existence of AMA-1 as homologs in different parasite genera 
is suggestive of its functional relevance (Taylor et al., 1990; Suarez et al., 1991). The 
specificity of the protective antibody to AMA-1 has been documented in P. falciparum 
(Hodder et al., 2001). Anti-AMA-1 antibodies from human and rabbit strongly inhibit 
merozoite invasion from homologous and heterologous strains of P. falciparum (Hodder 
et al., 2001). In addition, the inhibitory effects of the antibodies are within ectodomain of 
the ligands and are directed to the conserved and strain-specific epitopes (Hodder et al., 
2001).  
Rhoptries are complex organelles that contain numerous proteins, many of which 
are immunogenic (Dalrymple et al., 1993; Dubermetz et al., 1998; Gaur et al., 2004). 
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Rhoptry-associated proteins 1 (RAP-1) from B. bovis and Babesia bigemina play a role 
in invasion of these parasites (Suarez et al., 1991; Dubremetz et al., 1998; Yokoyama et 
al., 2002). The best-characterized rhoptry protein in B. bigemina and B. bovis is the 58- 
to 60-kDa rhoptry-associated protein 1 (RAP-1), which is detected on the merozoite 
surface in both species (Suarez et al., 1991; Suarez et al., 1994). RAP-1 is encoded by 
two genes in B. bovis and multiple polymorphic genes in B. bigemina (Suarez et al., 
1991; Yokoyama et al., 2002). Babesia bovis RAP-1 has an apical localization and is 
clearly detectable as a rhoptry component by immuno-electron microscopy (Dalrymple 
et al., 1993; Suarez et al., 1991). RAP-1-encoding genes also have been identified in 
Babesia canis, Babesia ovis, and Babesia divergens (Suarez et al., 1991). Members of 
the RAP family have retained four conserved cysteine residues and considerable 
sequence homology. Furthermore, several conserved oligopeptide motifs are shared by 
the different RAP-1 proteins (Dalrymple et al., 1993; Suarez et al., 1991). Despite 
polymorphism in nucleotide sequences located within the RAP-1 open reading frame in 
B. bovis and B. bigemina, defined B-cell surface epitopes and the molecular size are 
conserved (Suarez et al., 1994).  Conserved residues in amino-acid sequences in rhoptry 
proteins within and across genera indicate the importance of the role played by this 
parasite ligand in invasion (Taylor et al., 1990; Suarez et al., 1994). 
The ability of rhoptry-associated proteins to induce partial protective immunity 
against parasite challenge has been documented for several apicomplexan parasites 
(Mosqueda et al., 2002; Yokoyama et al., 2002). Protection was demonstrated with 
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Plasmodium sp. by using rhoptry protein RAP-1 (Anders et al., 1998; Mosqueda et al., 
2002; Gaffar et al., 2004).  
An erythrocyte-binding assay with the lysate of B. bovis merozoites proved the 
binding ability of RAP-1 to bovine erythrocytes (Yokoyama et al., 2002).  Moreover,  
anti-RAP-1-specific antibodies prevented the interaction of RAP-1 with bovine 
erythrocytes and these antibodies significantly inhibited the proliferation of B. bovis in in 
vitro culture (Yokoyama et al., 2002). These findings indicate that the RAP-1 plays a 
significant role in erythrocyte cell invasion by merozoites (Yokoyama et al., 2002; 
Gaffar et al., 2004).  
Thrombospondin-related anonymous protein (TRAP) is another miconemal 
protein found in Babesia that has analogy to their most closely related counterparts in 
P. falciparum (Scarselli et al., 1993; Sharma et al., 1996; Soren et al., 2000). The 
B. bovis TRAP has only been found during the asexual erythrocytic stage and is located 
at the apical complex. A 75-kDa protein is secreted in the extracellular milieu, which is 
recognized by TRAP antisera (Gaffar et al., 2004). In addition, specific antibodies to 
B. bovis TRAP inhibit bovine erythrocyte invasion by the merozoites.  
Plasmodium falciparum TRAP is detected in sporozoites rather than in 
merozoites (Gaffar et al., 2004; Yokoyama et al., 2006). TRAP homologues in 
Plasmodium spp. are identified as parasite ligands which interact with the host cell 
(Muller et al., 1993; Sultan et al., 1997). They share several adhesive domains that are 
not conserved. These findings indicate that TRAP is directly involved in both 
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recognition and invasion of host cells only in Plasmodium spp. and not in other 
apicomplexans.  
From the data above aimed at elucidating the role played by apicomplexan apical 
ligands in host cell invasion, AMA-1 appears to play a critical role in this process.  
RAP-1 proteins have high sequence homology and conserved oligopeptide motifs, but 
RAP-1 is encoded by two genes in B. bovis and multiple polymorphic genes in 
B. bigemina (Suarez et al., 1991; Yokoyama et al., 2002) indicating a lack of strict 
conservation. In addition, RAP-1 proteins are able to produce only a partial immunity 
during invasion by merozoites (Yokoyama et al., 2006), which suggests that this ligand 
plays a minor role in the process of invasion. 
TRAP involvement in host cell invasion needs further confirmation. TRAP has 
been implicated in gliding motility of Plasmodium and Toxoplasma (Muller et al., 1993; 
Sharma et al., 1996; Soren et al., 2000; Yokoyama et al., 2006). TRAP in malaria has 
been detected in sporozoites rather than in merozoites, whereas in B. bovis TRAP has 
only been found during the asexual erythrocytic stage, which indicates lack of 
conservation of this ligand between parasitic stages in apicomplexans. In addition, 
antibodies against TRAP do not inhibit invasion of erythrocytes by P. falciparum (Soren 
et al., 2000).  On the other hand, fragments of monoclonal IgG to a merozoite apical 
antigen inhibited P. knowlesi invasion of erythrocytes, immunization of mice with 
recombinant AMA-1 protected mice against infection with P. chabaudi, and protective 
immunity was induced in squirrel monkeys immunized with recombinant AMA-1 
antigen of P. fragile (Thomas et al., 1984; Collins et al., 1994; Anders et al., 1998). 
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 Evidence of strain specific protective immunity by anti-AMA-1 antibodies has 
been described in Plasmodium spp. (Anders et al., 1998). Cross protection has been 
demonstrated using P. falciparum AMA-1 anti-peptides antibodies to inhibit bovine 
erythrocyte invasion by B. bovis (Urquiza et al., 2000; Gaffar et al., 2004; Yokoyama et 
al., 2006). Complementation of P. falciparum AMA-1 with AMA-1 from P. chabaudi 
allows the human parasite P. falciparum to efficiently invade mouse cells (Triglia et al., 
2000).  These ligands therefore play a critical function in cell invasion by Plasmodia 
species. The remarkable conservation of the AMA-1 molecule within and acrross genera 
and its protective role make it an excellent candidate for developing efficient 
therapeutics and vaccine for apicomplexan pathogens (Waters et al., 1991; Denise et al., 
1996; Hodder et al., 2001). 
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CHAPTER II 
 
EXPRESSION PLASMID CONSTRUCT 
 
INTRODUCTION 
The objective of the line of experiments in this chapter was to prepare an 
expression plasmid construct with the B. microti ectodomain sequence. The BmAMA-1 
ectodomain sequence was amplified from the B. microti ama-1gene then cloned into the 
pET TOPO 101D expression vector, to provide a histidine-tagged fusion protein for 
affinity column capture. The plasmid construct carrying the correct sequence of the 
BmAMA-1 ectodomain in frame with the His-tag and the ATG initiation codon with no 
internal stop codon was selected for expression. 
MATERIALS AND METHODS 
Amplification of the Babesia microti ama-1 ectodomain  
The B. microti ama-1 ectodomain was amplified using  primers pETSigBm F (5'-
CAC CATGAACG CAAGACCC GC-3') and pETTmBm R (5’-GCCATARAAAGT-
CAATGGTGTTTGGTTCAATGTCTCACT-3') (Fig. 2) designed from the full sequence 
of  the B. microti AMA-1 gene according to manufacturer’s instructions (Champion pET 
Directional Expression kit; Invitrogen, Carlsbad, CA). The forward strand primer 
incorporated a 4-base overhang (5’CACC) directly preceding the ATG start codon. The 
B. microti ama-1 ectodomain was amplified using a high fidelity polymerase according 
to manufacturer’s instructions (Phusion High-Fidelity PCR Kit, New England Biolabs,  
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1   caaatgactaatgcagctaaacgaagcttaagcctcaatggctcgatttttaaatatgtt 60 
     Q  M  T  N  A  A  K  R  S  L  S  L  N  G  S  I  F  K  Y  V  
61   ttaatattttttttatttattttagtgctggacttccaactggcgacggtcagtgcagct 120 
     L  I  F  F  L  F  I  L  V  L  D  F  Q  L  A  T  V  S  A  A  
121  ctagcc>aacgcaagacccgcgcaccgtaaaattgttcataagcataaaaacagtggagca180 
     L  A   N  A  R  P  A  H  R  K  I  V  H  K  H  K  N  S  G  A  
181  aaaccgcgtcaccaagcaaaaaagcatgtgaatatcacggaggaggatgatgaggatggt 240 
     K  P  R  H  Q  A  K  K  H  V  N  I  T  E  E  D  D  E  D  G  
241  gaagtatacgaggaggatgaggaggatgactatgaagatacggattatgaagagttggaa 300 
     E  V  Y  E  E  D  E  E  D  D  Y  E  D  T  D  Y  E  E  L  E  
301  ttcaagccaataggggatgagagggataacccgtgggagtcttacatggaaaaatttaac 360   
     F  K  P  I  G  D  E  R  D  N  P  W  E  S  Y  M  E  K  F  N  
361  attcccaaggttcacggatctggagtttatgtggatctgggcaaaaacggcacttttaat 420 
     I  P  K  V  H  G  S  G  V  Y  V  D  L  G  K  N  G  T  F  N  
421  ggtaaaaaatatagaatggtcgcgggaaaatgcccagtttttgggaaaattatagaattt 480 
     G  K  K  Y  R  M  V  A  G  K  C1  P  V  F  G  K  I  I  E  F  481  tctagcggtgtagattacctctctcctgcaaacgacaccgccaaccccgcctttgggttt 540 
     S  S  G  V  D  Y  L  S  P  A  N  D  T  A  N  P  A  F  G  F  
541  ccatacacagttcctgcaggtaaaactattcgtacaaatgaaatacccaaaacttctaga 600 
     P  Y  T  V  P  A  G  K  T  I  R  T  N  E  I  P  K  T  S  R  
601  gggagaattagtatctcaaaatctgccgtgcaaacagatttgatatctcctgtcactgcc 660 
     G  R  I  S  I  S  K  S  A  V  Q  T  D  L  I  S  P  V  T  A  
661  aaaacactgaaagcatacgaatatgacggggatgatatattcaactgcgcctcctatgcc 720  
     K  T  L  K  A  Y  E  Y  D  G  D  D  I  F  N  C2  A  S  Y  A  721  agcgaattgatgatgagtagtgacagaaagtctgattacaaatatccatttgcctttgat 780 
     S  E  L  M  M  S  S  D  R  K  S  D  Y  K  Y  P  F  A  F  D 
781  ttgaaaactaaaacttgccacatcttatactctccgttgcaactaatccagggacctaag 840 
     L K  T  K  T  C3  H  I  L  Y  S  P  L  Q  L  I  Q  G  P  K  841  tattgtgataatgatggaaaagtggatagtggttccagcagtatgccttgtattaagccc 900 
     Y  C4  D  N  D  G  K  V  D  S  G  S  S  S  M  P  C5 I  K  P  901  gtgaaggacatgagtcaagaaatggtttatggatcttccttcatttacagggactggaaa 960 
     V  K  D  M  S  Q  E  M  V  Y  G  S  S  F  I  Y  R  D  W  K  
961  aataaatgtcccaatgcggcggtggcagatgcaatttttggtacctggaacggcacggct 1020 
    N  K  C6 P  N  A  A  V  A  D  A  I  F  G  T  W  N  G  T  A  1021 gcgttccaattcagaataggagattattcaaagcttctactcctgaaatttgcggtcaa  1080 
     C7 V  P  I  Q  N  R  R  L  F  K  A  S  T  P  E  I  C8 G  Q  1081 atagtgttcaaatatagtgcatcggatgcaccggaaaattatgaaactaaacgcagtgaa 1140 
     I  V  F  K  Y  S  A  S  D  A  P  E  N  Y  E  T  K  R  S  E  
1141 ggttctaaatttgcaaatgcaatctcatctggtgaccttggtgcagttgctaagattata 1200 
     G  S  K  F  A  N  A  I  S  S  G  D  L  G  A  V  A  K  I  I  
1201 atgcctgtcacaaactctcgcgcccaccactccaagggatggggcttcaattgggccaat 1260 
     M  P  V  T  N  S  R  A  H  H  S  K  G  W  G  F  N  W  A  N  
1261 tatgataggaataagcgtgaatgtggcttaatcgatgaggttccaaattgtctagttttc 1320 
     Y  D  R  N  K  R  E  C9  G  L  I  D  E  V  P  N  C10 L  V  F  1320 aagatgggaaacattgcattcaactccttgggttctccactagaggatgatatggaaaat 1380 
     K  M  G  N  I  A  F  N  S  L  G  S  P  L  E  D  D  M  E  N  
1381 ttcccttgcgaaatcaagtctttcgggtatattaccaagggaaatcctaatgatatcaat 1440 
     F  P  C11 E  I  K  S  F  G  Y  I  T  K  G  N  P  N  D  I  N 1441 agctatctcatttcatcgacccatcgtgatatgattcctaacgacgatggtattgagacc 1500 
     S  Y  L  I  S  S  T  H  R  D  M  I  P  N  D  D  G  I  E  T  
1501 ttgaatgctcgtagttgcagtggatactatgggaaaatcggtgcgaaggaaagtgagaca 1560 
     L  N  A  R  S  C12 S  G  Y  Y  G  K  I  G  A  K  E  S  E  T 1561 ttgaaccaaacaccattgactttytatggc<tttgggattattacgattataagcgctgca1620 
     L  N  Q  T  P  L  T  X  Y  G   F  G  I  I  T  I  I  S  A  A  
1621 atttttgtagtgctactagtgttattagtggtatttttgcgcaggctatccaaaaagaga 1680 
     I  F  V  V  L  L  V  L  L  V  V  F  L  R  R  L  S  K  K  R  
1681 tttaccaaggatgatgaagctttgttaaataagtatgatgaatttgaaggtagaaactac 1740 
     F  T  K  D  D  E  A  L  L  N  K  Y  D  E  F  E  G  R  N  Y  
1741 atgcatcgggggaatgatcataatgtagatgaaaacgatttttgggaaaagccgcaggtc 1800 
     M  H  R  G  N  D  H  N  V  D  E  N  D  F  W  E  K  P  Q  V  
1801 aggcccagcgaagtgactccaatccgaattgaacgaattgaatattaagtgccattttat 1860 
     R  P  S  E  V  T  P  I  R  I  E  R  I  E  Y  -  V  P  F  Y  
1861 agcttttattgtggcatttactgaatatttgtaaagctttaattggcgttaatttgtaca 1920 
     S  F  Y  C13 G  I  Y  -  I  F  V  K  L  -  L  A  L  I  C14 T  1921 ctaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 1956 
     L  K  K  K  K  K  K  K  K  K  K  K   
 
Figure 2. Babesia microti AMA-1 full gene sequence with predicted amino acid residues. 
The ectodomain is shown by < following the signal peptide (underlined) and > preceding 
the transmembrane region (underlined). Primer sequences (bold underline) and conserved 
cysteines C1-14 are shown. 
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Beverly, MA) in a 12.5 µl total reaction volume. The cycling protocol included a hot 
start at 98 C for 30 sec, followed by 25 cycles of  98 C for 10 sec, 67 C for 10 sec, and 
72 C for 1.5 min with a final extension at 72 C for 5 min. Amplified products were 
separated by 1%  agarose gel electrophoresis, stained with ethidium bromide (CLP, San 
Diego, CA) and viewed by UV transillumination. The size of the amplicon was 
determined by comparison to a 100 bp DNA size ladder (Invitrogen, Carlsbad, CA). 
Purification of the amplified B. microti ama-1 ectodomain  
The B. microti ama-1 ectodomain amplicon was purified using QIAGEN Quick 
Purification Kit (QIAGEN, Valencia, CA). Briefly, 5 volumes of Buffer PB1 were added 
to the sample and mixed by stirring with a pipette. The mixture was applied to the 
column and the flow-through collected by centrifugation in a 2 ml collection tube and 
discarded. The column was washed with 750 µl of Buffer PE and the flow-through was 
collected by centrifugation and discarded. The residual wash buffer was removed by a 
second centrifugation and discarded. The column was placed into a new 1.5 µl 
microcentrifuge tube then 30 µl of deionized water was added to the column and the 
B. microti ama-1 ectodomain amplicon was eluted by centrifugation. One microliter of 
the purified DNA was electrophoresed through and visualized on an ethidium bromide 
stained 1% agarose gel by ultraviolet transillumination. The DNA concentration was 
determined by spectrophotometry (NanoDrop ND-1000 Spectrophotometer, NanoDrop 
Technologies, Inc., Wilmington, DE).  
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Ligation and bacterial transformation 
The purified B. microti ama-1 ectodomain obtained above was ligated into the 
pET101/D-TOPO® C-terminal V5, 6xHis expression vector according to the protocol 
outlined in the Champion pET Directional TOPO Expression Kit (Invitrogen, Carlsbad, 
CA). A total volume of 6 µl of ligation reaction was prepared containing 8 ng of the 
purified PCR product and 1 µl of the pET101/D-TOPO vector. The reaction was mixed 
and incubated at room temperature for 5 min, then transferred to ice prior to 
transformation of TOP10 Competent E. coli cells.  
TOP10 Competent E. coli cells were transformed with the ligation product 
according to manufacturer’s instructions (Champion pET Directional TOPO Expression 
Kit, Invitrogen, Carlsbad, CA). Briefly, the cells were thawed on ice and 3 µl of ligation 
mixture from above was added and mixed gently with a pipette tip. The transformation 
mixture was incubated on ice for 20 min, then heat shocked for 30 sec at 42 C.  Then, 
250 µl of room temperature SOC (2% Tryptone, 0.5%Yeast Extract, 10 mm NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mm MgSO4, 20 mM glucose) was added and the culture 
incubated on a shaker at 37 C at 200 rpm for 1 hr. Two LB agar plates containing 
50 µg/ml carbenicillin were inoculated with 100 or 200 µl of culture and incubated 
overnight at 37 C.  
Selection of clones   
Colony PCR using pETTBm R and pETSigBm F primers was performed to 
detect clones carrying the BmAMA-1 ectodomain insert from among 24 colonies. 
Briefly, a total volume of 286 µl of master mix was made using 260 µl of 2X QIAGEN 
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PCR Buffer and 10.4 µl (104 pmol) each of the forward and reverse primers, and 5.2 µl 
of ultrapure water. A portion of each of the 24 selected colonies was transferred into 9 µl 
of ultrapure water and 11 µl of master mix was added to each tube. Two additional 
reactions with BmAMA-1 pDNA and water served as positive and negative control 
respectively. The cycling protocol included an initial denaturation for 2 min at 96 C, 
followed by 30 cycles of 96 C for 30 sec, 55 C for 30 sec and 72 C for 2 min, and a final 
extension at 72 for 10 min (PCR Express thermocycler, Hybaid). The resulting 
amplicons were analyzed on an ethidium bromide stained 1% agarose gel alongside a 
100 bp DNA ladder (Invitrogen, Carlsbad, CA) and viewed by UV transillumination. 
Expansion and plasmid DNA extraction of selected colonies 
 
Eight clones were selected based on the presence of the appropriate sized 
amplicon determined above. The clones were expanded in 10 ml LB broth containing 
50 µg/ml carbenicillin at 37 C and 200 rpm overnight. Plasmid DNA was prepared 
according to the manufacturer’s instructions (QIAGEN Plasmid DNA miniprep kit, 
QIAGEN, Valencia, CA). Briefly, the cultures were centrifuged to pellet the E. coli cells 
at 1800 g for 30 min, the supernatant was removed from each, and the pellets were 
resuspended in 500 l buffer P1. Lysis buffer P2 (500 l) was added to the suspension, 
which was then mixed by gently inverting the tube 6 times. Then, 700 µl buffer N3 
neutralization buffer was added and the suspension mixed immediately and thoroughly 
by inverting the tube 6 times. The tubes were centrifuged at 13,000 g for 10 min in a 
microcentrifuge. The supernatant was recovered and applied to the QIAprep Spin 
Column. The column was centrifuged for 60 sec and the flow-through was discarded. 
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The column was washed with 500 l of binding Buffer B, then the column was 
centrifuged for 60 sec and the flow-through discarded. Then, 750 l of wash buffer PE 
was added to the column then centrifuged for 60 sec. The flow-through was discarded 
then the column was centrifuged for an additional 60 sec to remove residual wash buffer. 
The column was placed in a new 1.5 ml microcentrifuge tube. To elute the plasmid 
DNA, 30 µl of nuclease free water was added to the center of each column, allowed to 
stand for 1 min, then centrifuged for 1 min to collect the flow-through. The collected 
plasmid DNA was size-analyzed on ethidium bromide stained 1% agarose and the DNA 
concentration determined by spectrophotometry (NanoDrop ND-1000 
Spectrophotometer, NanoDrop Technologies, Inc., Wilmington, DE). The presence of 
the BmAMA-1 ectodomain insert in the plasmid DNA was reconfirmed by PCR using 
primers pETTBm R and pETSigBm F. BmAMA-1 ectodomain inserts in 8 confirmed 
clones were sequenced (Davis Sequencing, Davis, CA) using T7 and T7 Reverse 
primers. The insert nucleotide sequence, orientation, and frame relative to the vector 
His-tag were analysed by SequencherTM 4.2 (Gene Codes Corporation, Ann Arbor, MI). 
RESULTS 
Amplification of the B. microti ama-1 ectodomain produced an amplicon of 
approximately 1500 base pairs (Fig. 2). After purification, the DNA concentration of the 
amplicon was 212.68 ng/µl.  
Cloning the B. microti ama-1 ectodomain amplicon into the pET101/D-TOPO 
vector yielded 16 colonies with inserts out of 24 tested (Fig. 3). Of these, eight were 
selected for expansion and plasmid DNA preparation. The purified plasmids were 
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confirmed to contain the insert by PCR (Fig. 4).  Upon sequencing, Clone 7 possessed 
the full nucleotide sequence (1563 bp) of the BmAMA-1 ectodomain in frame with the 
vector histidine tag and with no internal stop codons (Fig. 5). The ectodomain spans 
1563 bp with an additional 96 bp for the vector, which includes 18 bp for the 6 His-tag 
residues.  The DNA concentration of the BmAMA-1 Clone 7 plasmid was determined to 
be 212.68 ng/µl. This clone was used for recombinant protein expression.   
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Figure 3. Babesia microti AMA-1 ectodomain amplicon. Ethidium bromide-
stained 1% agarose gel.  Lane 1: 100 bp DNA ladder, 3: B. microti AMA-1 
ectodomain 1563 bp,  4: water control. 
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Figure 4.  Colony PCR amplicons.  Babesia microti ama-1 ectodomain. 1% agarose 
gel stained with ethidium bromide. Lanes 1 and 14, 100 bp DNA Size marker; Lanes 
2-12 and 16-27, tested colonies; Lane 13, B. microti ama-1 DNA control; Lane 15, 
water control. Clone 7 is indicated by an arrow.   
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Figure 5.  Plasmid constructs with B. microti ama-1 
ectodomain. Electrophoresed in 1% agarose gel Lanes 1 
and 8, 100 bp DNA size marker (100 to 2072 bp). Lanes 
2-7 and 10, cloned plasmid DNA. Lane 9 negative control. 
Clone 7 is indicated by an arrow.  
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CHAPTER IV 
 
BABESIA MICROTI AMA-1 RECOMBINANT PROTEIN 
INTRODUCTION 
The objective of this line of experiments was to express the B. microti AMA-1 
(BmAMA-1) ectodomain recombinant protein in a prokaryotic expression system. The 
expressed recombinant protein was enriched for use in downstream applications to 
determine its interactions with erythrocytes membrane proteins.  
MATERIALS AND METHODS 
 
Recombinant BmAMA-1 ectodomain protein expression in BL21 Star™ (DE3) One 
Shot® E. coli  
BL21 Star™(DE3) One Shot®  E. coli were transformed with BmAMA-1/pET 
Clone 7 according to manufacturer’s recommendations (Invitrogen, Carlsbad, CA).  
Briefly, the DNA (8 ng in 2 µl) was mixed gently into BL21 Star™(DE3) One Shot®  
cell suspension and then the mixture was incubated on ice for 30 min. The cells were 
heat-shocked for 30 sec at 42 C without shaking and the tube immediately transferred to 
ice. After addition of 250 l of room temperature SOC, the tube was incubated 
horizontally at 37 C for 30 min with shaking at 200 rpm.  
Recombinant protein pilot expression in BL21 Star™ (DE3) One Shot® E. coli  
The entire transformation reaction was added to 10 ml of LB broth containing 
carbenicillin (50 µg/ml) and the culture was grown overnight at 37 C with shaking at 
200 rpm. The overnight culture (500 l) was used to inoculate 10 ml of LB broth 
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containing carbenicillin and the cultures were grown for 2 hr at 37 C with shaking at 200 
rpm. The OD600 was checked and was about 0.65 (midlog phase). The cultures were 
divided into two 5 ml cultures, with addition of IPTG to a final concentration of 1.0 mM 
to one of the cultures. For 0 hr time point samples, a 500 l aliquot was collected from 
each culture, centrifuged at 13,000 g for 30 sec, the supernatant aspirated and discarded, 
and pellets frozen at –20 C for later analysis. The cultures were incubated at 37 C with 
shaking at 200 rpm and monitored over time for 6 hr with samples taken each hour as 
above.  
The collected samples were analyzed by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). Briefly, each pellet was resuspended in SDS-PAGE 
sample buffer according to manufacturer’s recommendations for the expression system 
used (Invitrogen), boiled for 5 min, then centrifuged briefly. The samples (10 µl each) 
were loaded on a vertical 12% polyacrylamide gel containing 10% SDS (12% SDS-
PAGE) (Laemmli et al., 1970) alongside a molecular weight marker (Low  
Range Molecular Weight Marker; BIO-RAD, Hercules, CA).  Electrophoresis was done 
in Mini PROTEAN II dual slab cell (BIO-RAD). The gel was run for 1 hr at 180 V. The 
gel was stained with Coomassie blue, a digital image acquired using AlphaEaseFc 
(Alpha Innotech, Berkeley, CA), and the expression profile was analyzed. 
Large-scale recombinant protein expression in BL21 Star™ (DE3) One Shot® E. coli  
One Erlenmeyer flask containing 100 ml of LB broth with carbenicillin 
(50 µg/ml) was inoculated with 2 ml of an overnight 10 ml culture obtained from a BL21 
Star™(DE3) One Shot®  E. coli transformation as above. The 100 ml culture was grown 
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for 2 hr at 37 C with shaking (225 rpm) to an OD600 of  0.5, then split into two 50 ml 
cultures. IPTG was added to a final concentration of 1.0 mM to one of the cultures and 
both cultures were incubated for 6 hr at 37 C with shaking at 200 rpm. Samples from 
induced and non-induced cultures were collected, processed, and analyzed as described 
above. 
Nickel affinity column enrichment of recombinant protein- Ni-NTA Spin Column   
The BmAMA-1 ectodomain recombinant proteins from BL21 Star™(DE3) One 
Shot®  E. coli were purified by nickel affinity for the fusion protein histidine tag from 
the 50 ml-culture pellets collected above. Purification was done under denaturing 
conditions according to the manufacturer’s protocols for purification (QIAGEN, 
Valencia, CA). Buffers B, C and E were prepared as follows: Buffer B: 8 M urea, 0.1 M 
NaH2PO4, 0.01 M Tris-Cl, pH 8.0; Buffer C: 8 M urea, 0.1 M NaH2PO4, 0.01 M Tris-Cl, 
pH 6.3; and Buffer E: 8 M urea, 0.1 M NaH2PO4, 0.01 M Tris·Cl, pH 4.5. Pellets were 
thawed for 15 min and resuspended in 1 ml Buffer B to lyse the bacteria. The suspension 
was then incubated with agitation for 1 hr at room temperature. To pellet the cellular 
debris, the lysate was centrifuged at 10,000 g for 30 min at room temperature. The 
supernatant was collected and 20 l of cleared supernatant was saved for SDS-PAGE 
analysis. The Ni-NTA Spin Column (QIAGEN) was equilibrated with 600 l Buffer B, 
centrifuged for 2 min at 700 g, and 600 l of cleared lysate supernatant was loaded onto 
the pre-equilibrated Ni-NTA Spin Column.  After centrifugation for 2 min at 700 g, the 
flow-through was collected and saved for subsequent analysis by SDS-PAGE. The Ni-
NTA Spin Column was washed 2 times with 600 l denaturing wash buffer by 
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centrifugation at 700 g for 2 min, and the wash flow-through saved for analysis by SDS-
PAGE. Bound His-tagged proteins were eluted 2 times with 200 µl Buffer E by 
centrifugation at 700 g for 2 min. Protein concentrations in both elutions were 
determined by spectrophotometry at wavelength 280 (Nanodrop ND-1000 
Spectrophotometer, Nanodrop Technologies, Inc., Wilmington, DE).   
SDS-PAGE sample buffer was added to each sample collected above and mixed. 
The samples were boiled for 5 min, centrifuged briefly, and 10 µl each were loaded into 
lanes of a 12% SDS-PAGE gel alongside a molecular weight marker (Low range 
molecular weight marker BIO-RAD, Hercules, CA) and electrophoresed at 180 V for 1 
hr. The gel was stained with Coomassie blue overnight and destained with a solution of 
45% H2O, 45% methanol and 10% Glacial Acetic Acid. A digital image was acquired 
using AlphaEaseFc (Alpha Innotech, Berkeley, CA), and the expression profile was 
analyzed. 
Nickel affinity column enrichment of recombinant protein using QIAExpress FAST 
START   
Denaturing lysis buffer (pH 8.0), denaturing wash buffer (pH 6.3), and 
denaturing elution buffer (pH 4.5) were prepared according to manufacturer’s 
instructions (QIAExpress FAST START Purification KIT, QIAGEN, Valencia, CA) and 
stored at 4 C until use. Five pellets from 50-ml of 6 hr induced cultures were removed 
from frozen storage at -80 C and 20 l of  protease inhibitors cocktail (SIGMA Aldrich, 
St. Louis, MO) was stirred into each pellet thawed at room temperature. The pellets were 
refrozen for 15 min at –80 C, then thawed again by stirring gently at room temperature. 
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Two ml of denaturing lysis buffer prepared above containing protease inhibitors were 
added to each pellet and the pellets were resuspended by stirring gently. The suspensions 
were incubated at room temperature for 60 min and swirled to mix gently every 15 min. 
To pellet the cellular debris, the resulting bacterial cell lysates were transferred to 1.5 ml 
screw cap conical microtubes and centrifuged at 10,000 g at room temperature for 30 
min. The supernatants, presumed to contain the recombinant proteins, were pooled from 
all tubes, and a 10-l aliquot of the supernatant was removed for SDS-PAGE analysis. 
An equal volume of 2X SDS-PAGE sample buffer was added to the sample and the 
sample was stored frozen at -20 C until analysis.   
The resin in a Fast Start Column (QIAGEN) was gently resuspended by inverting 
the column 3 times. The seal at the outlet of the column was broken and the screw cap 
opened to allow the storage buffer to drain out. Pooled supernatant (10.2 ml) was applied 
to the column and the flow-through fraction was collected. A 10-l aliquot was removed 
and treated as above for SDS-PAGE analysis. The column was washed 2 times with 4 ml 
of denaturing wash buffer with protease inhibitors. Both wash fractions were collected 
and samples collected for later analysis as above. Two applications of 1 ml denaturing 
elution buffer were collected as flow-through and samples of each prepared for later 
analysis as described above. Protein concentrations in both elutions were determined by 
spectrophotometry at wavelength 280 (Nanodrop1000) and the samples were analyzed 
by SDS-PAGE as described above.  
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Western blot analysis of enriched BmAMA-1 ectodomain fusion protein 
 Each sample was adjusted to 10 µl by addition of ultrapure water and the  
appropriate amount of 2X Laemmli buffer (4% SDS, 20% glycerol, 10%  2-
mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris HCl, pH approx. 6.8), 
boiled for 5 min and loaded into a lane of a 12% SDS-PAGE. The gel was 
electrophoresed at 180V for 1 hr to separate the proteins, which were then transferred 
overnight to either nitrocellulose (NC) or PVD (BIO-RAD, Hercules, CA) membranes at 
30 volts (30 V, 40 mA-90 mA) followed by 2-hr transfer at 100 volts (150 m-240 mA) 
using a continuous cooling system. The membrane was removed from the transfer 
cassette and incubated in 10 ml blocking buffer composed of Tris Buffered Saline (TBS) 
with 5% nonfat dry milk for 1 hr with gentle agitation on a rocker platform. Then, the 
membrane was washed 2 times with 20 ml of TBS containing 0.5% Tween 20 (TBST) 
with gentle agitation for 5 min each. The membrane was then incubated in 10 ml mouse 
anti-His (C-term) monoclonal antibody (Invitrogen, Carlsbad, CA) diluted 1:5000 in 
blocking buffer with gentle agitation overnight at 4 C. The membrane was washed 2 
times in 20 ml TBST 5 min each with gentle shaking, then incubated in 10 ml of alkaline 
phosphatase conjugated goat anti-mouse antibody (ImmunoPure Goat Anti-Mouse 
IgG+IgM (H+L) (min x BvHnHs Sr Prot), Pierce, Rockford, IL) diluted 1:10,000 in 
blocking buffer with gentle agitation for 1 hr at room temperature. The membrane was 
washed 2 times with 20 ml TBST containing 0.5% Tween 20 for 5 min each with gentle 
shaking. Then, the membrane was incubated in 10 ml 5-bromo-4-chloro-3-indolyl-
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phosphate/Nitroblue Tetrazolium substrate (Sigma Fast BICP/NBT, Sigma, St Louis, 
MO). 
Recombinant BmAMA-1 ectodomain fusion protein expression in BL21 Codon Plus 
E. coli  
Recombinant BmAMA-1 ectodomain protein was expressed in BL21 Codon Plus 
(DE3)-RIPL Competent Cells according to the manufacturer’s instructions (Stratagene, 
La Jolla, CA). A 100 l aliquot of BL21 Codon Plus (DE3)-RIPL chemically competent 
E. coli cells was mixed with 2 µl of 1:10 dilution of XL10-Gold -mercaptoethanol in 
14-ml BD Falcon polypropylene round bottom tube on ice. The tube content was swirled 
to gently mix every 2 min for 10 min. BmAMA-1/pET Clone l7 (10 ng) was added to 
the cells and swirled gently to mix. The transformation was incubated on ice for 30 min, 
and then heat pulsed in a 42 C water bath for 20 sec. The reaction was incubated on ice 
for 2 min and 0.9 ml of preheated (42 C) SOC medium was added to the reaction and 
incubated at 37 C for 1 hr with shaking at 225 rpm. After incubation, 50 and 200 µl of 
transformed cells were used to inoculate LB agar plates containing carbenicillin.   
 Identification of transformed colonies 
Colony PCR was performed on 10 colonies to determine if the BmAMA-1 
ectodomain insert was present. PCR master mix was prepared using 100 µl of 2X 
QIAGEN PCR buffer (QIAGEN, Valencia, CA), 4 µl of BmAMA-1 specific primers 
pETSigBm F and pETTmBm R (40 pmol each) and 2 µl of ultrapure water. Ten colonies 
were selected and a portion of each added to 9 µl aliquots of water. Eleven l of the 
master mix was then added to each tube, and the tubes placed in a PCR Express 
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thermocycler (Franklin, MA, U.S.A) along with a negative control. Amplification was 
done with an initial denaturation at 94 C for 2 min, then 30 cycles of  94 C for 30 sec, 50 
C for 30 sec and 72 C for 2 min with a final extension at 72 C for 10 min.  
Recombinant protein pilot expression in BL21 Codon Plus E. coli 
 
Three single colonies were used to inoculate duplicate 1 ml aliquots of LB broth 
containing 50 g/ml of chloramphenicol and 50 g/ml carbenicillin. The transformed 
bacteria were grown overnight at 37 C, 220 rpm, then one set was used to inoculate three 
20 ml LB broth cultures without antibiotics. The cultures were grown for 2 hr then 
induced with 1.0 mM IPTG. At time 0 hr, 20-l samples of culture were collected for 
later SDS-PAGE analysis. The cultures were grown for 4 hr after induction and 20-µl 
samples were again collected for SDS-PAGE analysis. The remaining culture was 
centrifuged to pellet the E. coli, the supernatant was removed, and the pellet stored 
frozen at -80 C.  
Large-scale expression in  BL21 Codon Plus E. coli   
The second set of 1-ml cultures from the duplicate sets above was used to 
inoculate 5 ml LB broths containing 50 g/ml of chloramphenicol and 50 g/ml 
carbenicillin, which were then incubated overnight at 37 C. Each 5 ml overnight culture 
was used to inoculate 100 ml LB broth with no selection antibiotic. The cultures were 
grown for 2 hr then induced with 1.0 mM IPTG and incubated for 4 hr at 37 C, 220 rpm. 
At time 0 hr, 20-l samples of culture were collected for SDS-PAGE analysis. The 
cultures were grown for 4 hr after induction and 20-µl samples were again collected for 
SDS-PAGE analysis. Protein expression in samples collected before and 4 hr after 
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induction were analysed on SDS-PAGE stained with Coomassie blue (BIO-RAD, 
Hercules, CA).   
Nickel affinity enrichment using NI-NTA Spin Column  
Enrichment of the expressed recombinant BmAMA-1 fusion protein was done as 
described above. The samples were analyzed by SDS-PAGE stained with Coomassie 
blue and by Western blot analysis.  
Nickel affinity column enrichment using QIAExpress FAST START   
Native lysis buffer, wash buffer and elution buffer were prepared according to 
the manufacturer’s instructions (QIAGEN, Valencia, CA). The pellets from 250 ml 
BL21 Codon Plus culture (Table 1) stored at –80 C were thawed on ice and resuspended 
in 10 ml of the prepared buffer. The suspension was incubated on ice for 30 min, mixing 
3 times gently by swirling the contents. The lysate was centrifuged at 14,000 g for 30 
min at 4 C to pellet the cellular debris. A 5 l aliquot of the cell lysate supernatant was 
saved for SDS-PAGE analysis and the remainder was stored at –20 C for Western blot 
analysis. 
The FAST START column protocol as given above was utilized except for the 
buffers which were designed for the native protein enrichment procedure. Aliquots were 
analyzed by SDS-PAGE as previously described.  
Enrichment of expressed protein from BL21 Codon Plus E. coli was 
accomplished under denaturing conditions as described above. Samples were collected 
as previously described.  
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SDS-PAGE analysis of the enriched recombinant protein 
Samples were analyzed by SDS-PAGE gel stained with Coomassie blue and by 
Western blot analysis.  No band was observed in the elutions from native enrichment 
instead the protein was found in the cell lysate and the cleared lysate flow-through. 
Protein concentrations from denaturing enrichment were determined at wavelength 280 
(Nanodrop1000). 
Other recombinant protein enrichments using QIAexpress FAST START   
BugBuster (Novagen, Madison, WI) protein extraction reagents were used to 
extract soluble protein from 100 ml culture pellet of transformed BL21 Codon Plus 
E. coli. Prechilled microfuge tubes at 4 C were used to process samples in this 
experiment. First the weight of the E. coli pellet collected from 100 ml transformed 
BL21 Codon Plus culture was determined. The pellet was resuspended in BugBuster 
lysis buffer (Novagen) at a rate of 1 g in 5 ml of buffer containing 10 µl/g lysonase and 
protease inhibitors. The lysate was incubated for 15 min at room temperature by slow 
rotation, then aliquoted in 2 ml snap cap tubes. The tubes were centrifuged at 16,000 g  
for 20 min at 4 C. Supernatants were collected and pooled then kept on ice. Protein 
concentration was determined on Nanodrop 1000, then the supernatant was loaded onto 
the FAST START column and the flow-through was collected. The column was washed 
2 times with FAST START denaturing wash buffer containing protease inhibitors. The 
flow-through was collected. Bound BmAMA-1 was eluted with 1 ml denaturing elution 
buffer pH 4.   
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A pellet from 10 ml culture of transformed BL21Codon PLUS RIPL (Invitrogen, 
Carlsbad, CA) was used for enrichment using His-Select resin (Sigma). The pellet was 
frozen at –80 C then thawed on ice 3 times in the presence of  protease inhibitor cocktail 
(Sigma, Aldrich, CA). The pellet was stirred to mix between cycles.  
For enrichment under native conditions, the pellet was resuspended after the final 
cycle in 400 µl of native lysis buffer (FAST START) and mixed well. Ten l of the 
suspension was removed for SDS-PAGE analysis. The suspension was incubated on ice 
for 30 min, mixed 3 times by swirling while incubating, then centrifuged at 14,000 g for 
30 min at 4 C. Supernatant was collected in small snap cap tubes and the protein 
concentration was measured. Protease inhibitors were added, then the tubes were labeled 
and stored at –80 C.  
For enrichment under denaturing conditions, the pellet was resuspended in 400 µl 
denaturing lysis buffer (FAST START) and mixed.  Ten µl of the suspension was 
removed for SDS-PAGE analysis. The suspension was incubated 1 hr at room 
temperature with mixing by swirling 3 times during incubation. The suspension was 
centrifuged at 14,000 g for 30 min at room temperature. The supernatant was collected, 
protease inhibitors were added, and the supernatant was stored at –80 C. 
Preparation of Sigma His–select nickel affinity gel (Sigma, Aldrich, CA)  
Aseptically, the His-select affinity gel was resuspended by inverting several 
times. Aliquots of 25 µl resuspended His-select gels were placed in two 1.5 ml screw 
cap microfuge tubes on ice. Tubes were centrifuged 30 sec at 5000 g to pellet the gel. 
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The supernatant was discarded and the gel was washed 2 times with 200 µl of sterile 
distilled water.  
Enrichment under native conditions 
One of the 25 µl aliquots of washed His-select gel was equilibrated with 200 µl 
of native equilibration buffer pH 8.0 from FAST START Kit (QIAGEN). The tube was 
centrifuged for 30 sec at 5000 g and the native equilibration buffer was removed. One 
hundred µl of clarified BmAMA-1 recombinant fusion protein prepared using native 
lysis buffer (FAST START Kit, Sigma) was added and mixed gently for 1 min. The tube 
was centrifuged as indicated above to pellet the gel. Unbound fusion proteins were 
removed by centrifugation. The gel was washed 2 times by adding 500 µl of native wash 
buffer pH 8.0. The tube was centrifuged as above and the wash buffers were saved as a 
pool for SDS-PAGE analysis. Bound fusion protein was eluted 2 times with 50 µl of 
elution buffer (50 mM sodium phosphate, pH 8; 0.3 mM Sodium chloride, 250 mM 
imidazole). First the gel was mixed with 50 l of the elution buffer by inverting gently 
for 1 min, then centrifuged for 30 Sec at 5000 g to collect the BmAMA-1 ectodomain 
fusion protein.  
Enrichment under denatured conditions  
Two hundred µl of denaturing lysis buffer (FAST START, QIAGEN) was added 
to a 25-µl aliquot of the washed His-select gel and centrifuged for 30 sec at 5000 g. The 
supernatant was removed then 100 l of clarified BmAMA-1 recombinant fusion protein 
prepared using denaturing lysis buffer (FAST START Kit, QIAGEN) was added to the 
gel and mixed gently for 1 min. Tube was centrifuged  for 30 sec at 5000 g to pellet gel 
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bound fusion protein and to remove unbound protein. The gel was washed 2 times by 
centrifugation by adding 500 l of denaturing wash buffer, pH 6.3. Wash buffers were 
collected as a pool for SDS-PAGE analysis. Bound BmAMA-1 ectodomain fusion 
protein was eluted by adding 50 µl of denaturing elution buffer, pH 4.5 as above.  
RESULTS 
 A summary of the expression trials and results is shown in Table 1. Overall, the 
best expression of recombinant BmAMA-1 fusioin protein was achieved using BL21 
Star DE3 E. coli (Fig. 6).  Nickel affinity capture using QIAExpress FAST START Kit 
method produced the best BmAMA-1 ectodomain recombinant protein (Figs. 7 and 8).  
Enrichment of BmAMA-1 ectodomain recombinant protein from BL21 Star DE3 
E. coli or BL21 Codon Plus under native conditions was unsuccessful (not shown). 
Nickel affinity capture of BmAMA-1 fusion protein using denaturing conditions resulted 
in enriched BmAMA-1 recombinant protein preparations with either the Spin Column or 
FAST START gravity flow (Figs. 7-9). The expected size for the recombinant BmAMA-
1 ectodomain fusion protein was 58.1 kDa, but the elution showed multiple bands in 
SDS-PAGE stained with Coomassie blue and these were confirmed by Western blot 
analyses (Figs. 7-9). The multiple bands may have been due in part to lack of addition of 
protease inhibitors in the purification buffers in some of the assays (example in Fig. 8). 
With the FAST START enrichment, the recombinant BmAMA-1 ectodomain fusion 
protein band at 58 KDa was more prominent in Western blot analysis (Figs. 7 and 8), but 
when enriched by the Spin Column, the signal produced in all these bands appears to be 
the same whether assayed by Coomassie blue or by Western blot analysis (Fig. 9).  
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Table 1.  Summary of BmAMA-1 ectodomain recombinant protein expression trials. 
 
 
*CB, Coomassie blue  
** WB, Western blot 
 Date Culture 
amount 
E. coli 
BL21 strain 
SDS-
PAGE 
Nickel 
column 
Denaturing 
or Native 
Resulting 
Bands(kDa) 
10.6.07 50  ml Star DE3 CB* NI-NTA  Denaturing  
10.7.07 " " " " "  
10.8.07 " " " " "          33  
10.8.07 " " " " " 58,53,43,33,23 
10.11.07 " " " " " 58,53,43,33,23 
10.12.07 " " " " " 58,53,43,33,23       
10.12.07 " " " " " 58,54,43,37      
10. 16.07 " " WB** " " 58 
10.17.07 " " WB " " 58,54,43,37      
10.18.07 250 ml Codon Plus CB " Native           
10.21.07 100 ml Star DE3 " FAST 
START 
" 80,76,54,43,37,33 
10.25.07 20 ml Codon Plus " NI-NTA  Denaturing            58 
10.26.07 " Star DE3 " " "  
10..28.07 " Codon Plus " " "            58 
10.31.07 " " " " "  
11.4. 07 " " " " "  
11.5.07 " " " " "  
11.6.07 " " " FAST 
START 
"         
11.9.07 50 ml " CB, WB NI-NTA 
Spin  
Denaturing           58 
11.14.07 " " " FAST 
START 
      "  58, 46,43 
11.19.07   250 ml  " "      "       "  58, 46,43,33,30       
12.1.07 100 ml " CB His select  
Sigma 
Native          
12.5.07 " " " BugBuster 
Novagen 
   "  
3.1.08  200 ml Star DE3 " His select 
Sigma 
Denaturing  
3.3.08     " " " BugBuster 
Novagen 
Denaturing   
3.4.08 250 ml " " FAST 
START 
Denaturing   58,36,33,30   
3.5.08     " " "        "  Denaturing   58, 49, 36 
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The detection of these bands in Western blot assays probed with anti-His tag 
monocolonal antibody indicates that these bands are all histidine rich proteins or 
possibly breakdown products of the BmAMA-1 ectodomain fusion protein. 
  
 
 
 
 
 
 
 
      
 
 
 
 
Figure 6. Timeline expression of recombinant BmAMA-1 ectodomain in BL21  
STAR DE3 E. coli. Lane 1, molecular weight marker. Lanes 2 through 8, IPTG  
Non-induced (NI) and Induced (I) samples over time as indicated. Arrow,  
   recombinant BmAMA-1 ectodomain.  
 
 
 
 
                                              
 
Figure 7. SDS-PAGE of enriched (FAST START) BmAMA-1 ectodomain fusion 
protein expressed in BL21 Codon Plus E. coli. Lane 2, E. coli lysate; Lane 3, cleared  
E. coli lysate flow-through after binding to the column. Lanes 4 and 5, first and second 
washes. Lanes 6 and 7, eluted BmAMA-1 ectodomain fusion protein.
 1      2       3     4      5      6      7      8  kDa 
 
   100 
     97 
 
     54 
 
     37 
 
     29 
 
 
     20 
 
  
  42 
 
 
Figure 8.  Western blot of His tag B. microti AMA-1 ectodomain fusion protein 
expressed in BL21 Codon Plus. Enriched by FAST START. Lanes 1 and 8, molecular 
weight marker. Lane 2, E. coli lysate cleared supernatant. Lane 3, supernatant flow-
through. Lanes 4 and 5, first and second wash.Lanes 6 and 7, B. microti AMA-1 
ectodomain fusion protein (58.1 kDa) elutions 1 and 2, respectively. 
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Figure 9.  BmAMA-1 ectodomain fusion protein expressed in BL21 DE3. Ni-
NTA spin column enrichment. (A) Coomassie blue stained 12% SDS-PAGE. 
Lane 1, molecular mass marker. Lane 2, E. coli lysate. Lanes 5 and 6, first and 
second washes. Lanes 7 and 8, first and second elutions of the fusion protein. 
(B) Western blot probed with anti-Histidine tag antibody. Lanes 1 and 10, 
molecular weight marker. Lane 3, cleared lysate. Lane 4, first flow-through. 
Lanes 5 and 6, first and second washes after binding. Lanes 8 and 9, first and 
second elutions of His-tagged recombinant protein (arrow, 58.1 kDa 
recombinant AMA-1). 
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            Transformed BL21 Codon Plus E. coli were confirmed by colony PCR before 
expression. Of eight colonies tested, all possessed the B. microti ama-1 insert (Fig. 10).  
Samples collected over 6 hours and analyzed according to the manufacturer’s protocol 
showed very little increase in the intensity of the 58.1 kDa protein band over time, but 
the best expression was observed at 4 hr following IPTG induction (not shown). When 
larger samples (500 µl) were collected and the E. coli pellets were analyzed, marked 
differences in protein expression were observed between non induced and induced 
bacteria.  The best recombinant expression was observed at 4 hr post IPTG induction 
(Figs. 11 and 12).  
 
 
    
 
 
 
  
 
 
 Protein enrichment from larger samples under denaturing conditions using NI-
NTA Spin Column produced low yield after purification of 50 ml pellet by NI-NTA 
Spin Column (not shown). This possibly due to the amount of cleared cell lysate 
supernatant processed on the Spin Column, which was 600 µl on the Spin Column 
           1    2   3    4   5  6  7  8  9  10  11 
            
       
BP 
 
2072 
1500 
 
 
   
600 
 
 
100 
Figure 10. Colony PCR products. BL21 Codon Plus E. coli clones transformed by 
pET/ BmAMA-1 ectodomain construct. Lane 1, 100 bpDNA size marker. Lanes 2 
through 9, BmAMA-1 ectodomain amplicons from individual colonies. Lane 11, 
BmAMA-1 DNA control.  
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instead of 1 ml by FAST START.  The elution for both was done in 50 µl denaturing 
elution buffer, resulting in less concentrated protein yield for the Spin Column.  
                                  
 
Figure 12. SDS-PAGE of expressed BmAMA-1 ectodomain fusion protein in Codon 
Plus E. coli. Cultures from 4 clones, 1, 2, 3, and 4, non-induced (N) and induced (I) 
samples from each 4 hours after induction.  Molecular weight marker in first lane. 
 
 
                
            Clone 1    Clone 2    Clone 3 
                                N       I              N       I               N       I 
                      
 
Figure 11. Expression of BmAMA-1 ectodomain in three colonies of BL 21 
Codon Plus E. coli. Samples from induced and non-induced cultures collected 6 
hr post IPTG induction. Clones 1, 2, 3 non- induced (NI) and induced (I) 
samples are indicated. Arrow, BmAMA-1 recombinant protein. Coomassie blue 
stained SDS-PAGE.   
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  Purification of recombinant BmAMA-1 fusion protein from Codon Plus E. coli 
pellets from large-scale cultures using QIAExpress FAST START Kit under denaturing 
conditions produced prominent BmAMA-1 ectodomain protein bands along with weaker 
additional protein bands evident in Western blot analysis as mentioned above (Figs. 8 
and 9).  The multiple bands were observed might indicate that other histidine rich 
proteins bound to the nickel column were not removed by washing and were eluted 
along with BmAMA-1 ectodomain fusion protein. These eluted proteins could be 
contaminants or truncated breakdown products of BmAMA-1 fusion protein that carry 
the His-tag.   
Expression was optimal at 3 hours post induction as evidenced by SDS-PAGE 
analysis of induced (I) and non induced (NI) samples over time (Fig. 6). All subsequent 
large scale expressions were grown for 3 hours following induction with 1 mM IPTG 
(Fig. 13).  A clone from transformed BL21 STAR DE3 E. coli cell yielded a stronger 
BmAMA-1 ectodomain fusion protein band (58.1 kDa) as shown on SDS-PAGE stained 
with Coomassie blue (Fig. 14). Two FAST START nickel affinity capture procedures 
under denaturing conditions using pellets from 250 ml transformed BL21 STAR DE3 
E. coli culture produced 0.28 and 0.29 mg/ml for elution 1 and 2, respectively (Fig. 14) 
and 0.24 and 0.83 mg/ml for elution 1 and 2, respectively (Fig.15). 
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Figure 14. SDS-PAGE analysis of BmAMA-1 ectodomain enriched protein. Lanes 1 and 
9, molecular weight marker. Lane 2, starting E. coli lysate. Lane 3, cleared lysate. Lane 
4, flow-through after binding. Lanes 5 and 6, first and second washes. Lanes 7 and 8, 
eluted bound protein. Coomassie blue stained. 
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Figure 13. SDS-PAGE of expressed BmAMA-1 ectodomain fusion protein. Large 
scale cultures from 4.  Lanes 1 and 8, molecular weight marker. Lanes 2-9, non-
induced and induced samples from the same cultures as indicated.   Coomassie blue 
stained. 
 kDa 
 
 
    100 
      97 
 
 
      
      54 
 
 
      37 
 
       
      29 
 
  
  47 
   
            
                              
 
Figure 15. BmAMA-1 ectodomain enriched protein. SDS-PAGE. Lanes 1 and 9, 
molecular weight marker. Lane 2, E. coli lysate. Lane 3, cleared lysate. Lane 4, flow-
through after binding. Lanes 5 and 6, first and second washes. Lanes 7 and 8, eluted 
bound protein. Coomassie blue. 
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CHAPTER V 
PROTEIN-PROTEIN INTERACTIONS 
BETWEEN PARASITE AND HOST ERYTHROCYTE 
 
INTRODUCTION  
The aim of this chapter was to determine valid interactions between BmAMA-1 
ectodomain protein and the receptors on the host erythrocyte. The role of many ligands 
(RAP, TRAP, AMA-1) in host cell invasion by apicomplexan has been studied. AMA-1 
appears to be critical in this process as demonstrated by the ability of anti-AMA-1 to 
inhibit host cell invasion in vitro and in vivo as well. AMA-1 proteins when released by 
the parasite during cell invasion bind to the erythrocyte surface receptors thus enabling 
the parasite to invade the cell. Knowledge of a true interaction between BmAMA-1 
ectodomain and the host cell will enable in vitro and in vivo studies to inhibit parasite 
invasion of the host cell. Our first objective was to determine that there is an interaction 
between the B. microti AMA-1 ligand and its putative receptors on the host erythrocyte. 
In some apicomplexans, such as Plasmodium falciparum, Babesia divergens, and 
Babesia bovis, these receptors have been shown to be the sialoglycoproteins of the 
RBCs, notably Glycophorin A and B, which are the most prominent. However, the 
composition of these residues that react to the parasite ligand (AMA-1) may be species 
specific. The analysis of interacting bands by tandem mass spectrometers can lead to 
structural information on the host cell receptors involved. In conclusion, determination 
of the interaction between BmAMA-1 ectodomain and analysis of the structure of the 
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cell binding partner structures are crucial in design of therapeutics and vaccines to 
counter babesiosis caused by B. microti.  Here we used far Western blot analysis, 
immunocapture and immunofluorescent antibody test (IFAT) to demonstrate interactions 
between the B. microti AMA-1 and its interacting receptors on the host cell membrane.  
MATERIALS AND METHODS  
Red blood cell (RBC) membrane preparation  
Mouse, human, and horse RBC membrane preparations were made according to 
the protocol below. Whole blood was collected in Alsever’s solution, then transferred to 
prechilled microfuge tubes which were kept cold throughout the process. The blood was 
centrifuged at 300 g for 30 min at 10 C to pellet the cells. The buffy coat was removed, 
and the RBC pellet was washed 3 times by centrifugation in several volumes of cold 
Dulbecco’s PBS, pH 7.2, with the buffy coat removed at each wash. The pellets were 
combined after the final wash. To each ml of packed RBC, 40 ml cold 5 mM Na2HPO4, 
pH 8.0 with protease inhibitor (Protease Inhibitor Cocktail, SIGMA Aldrich, St. Louis, 
MO) was added and the cells resuspended in this solution. The tubes were completely 
immersed in ice for 30 min, then the resulting RBC lysate was dispensed in 1.3 ml 
volumes into 1.5 ml conical snap-top microfuge tubes on ice. The lysates were 
centrifuged at 15,000 g for 10 min at 4 C and the supernatant removed and discarded. 
The resulting RBC membranes were washed 2 times in 5 volumes of 5 mM Na2HPO4, 
pH 8.0 containing protease inhibitors, then 2 times with PBS containing protease 
inhibitors by centrifugation at 15,000 g for 10 min at 4 C. After the last centrifugation, 
the supernatant was removed and the protein concentrations of the purified RBC 
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membrane pellets were determined by spectrophotometry (NanoDrop ND-1000 
Spectrophotometer, NanoDrop Technologies, Inc., Wilmington, DE). The RBC 
membrane preparations were stored frozen at -80 C. 
Far Western blot analysis  
The far Western blot protocol is depicted in the schematic shown in Figure 16. 
For this assay, 60 g of each RBC membrane preparation was loaded per lane on a 
vertical 12% polyacrylamide gel containing 10% SDS (Laemmli et al., 1970). 
Electrophoresis was done in Mini PROTEAN II dual slab cell (BIO-RAD, Hercules, 
CA). The gel was run for 1 hr at 180 V. After electrophoresis the separated proteins were 
electrophoretically transferred to a nitrocellulose membrane (Towbin et al., 1973).  
Transfer was done overnight in a Mini-Trans-Blot Cell (Bio-Rad) at 30 volts, then at 100 
volts for 2 hr the next morning. The nitrocellulose membrane was cut into strips 
corresponding to protein lanes and one strip was stained with Ponceau Red stain (Sigma, 
Saint Louis, MO) to visualize the transferred protein bands. The strips were incubated in 
10 ml blocking buffer composed of Tris Buffered Saline (TBS) with 5% nonfat dry milk 
and 0.05% Tween 20 for 2 hr with gentle agitation on a rocker platform, then washed 4 
times with 300 ml PBS for 20 min each. The strips were incubated overnight at 4 C in 
purified BmAMA-1 ectodomain fusion protein diluted in blocking buffer at a 
concentration of 6 g/ml. After blocking, control strips were washed once with PBS, 2 
times with PBS containing 0.05% Tween 20, and once more with PBS for 20 min with 
agitation each wash and then stored overnight at 4 C. The next day, the strips incubated 
with BmAMA-1 ectodomain fusion protein were washed 4 times as described above. 
  
  51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Schematic of the far Western blot assay protocol. 
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The strips and primary antibody (unreacted control strip) were incubated in 
mouse anti-His primary monoclonal antibody (Invitrogen, Carlsbad, CA) diluted 1:5000 
for 1 hr at room temperature with slow rotation. After incubation, the strips were washed 
4 times as above. The strips and the secondary antibody control (unreacted control strip), 
were  incubated in 10 ml of goat anti-mouse Horse Radish Peroxidase conjugated 
(Pierce, Rockford, IL) diluted 1:10,000 in blocking buffer with gentle agitation for 1 hr 
at room temperature. All strips were washed as above, then incubated in Immobilon 
Substrate for 5 min according to the manufacturer’s instructions (Millipore, Billerica, 
MA). Strips were blotted to drain off excess substrate then analyzed by X-ray 
radiography. 
Immunoprecipitation 
 
To prepare soluble RBC membrane proteins, 2 mg of human purified RBC 
membrane (above) was added to 1 ml solubilization buffer (50 mM Tris pH 7.5, 150 mM 
NaCl, 1% sodium deoxycholate) containing protease inhibitors and incubated on ice for 
1 hr. After centrifugation at 13,000 g for 5 min at 4 C, the supernatant containing 
solubilized membrane proteins was recovered. The protein concentration was 
determined as above and 14 µg of soluble protein was analysed on an SDS-PAGE gel 
stained with Coomassie blue.    
BmAMA-1 ectodomain recombinant protein was enriched from a 50 ml induced 
culture pellet of transformed BL21 Star DE3 E. coli (Table 1). The pellet was subjected 
to 3 freeze/thaw cycles in liquid nitrogen. Then, it was resuspended in 5 ml B-Per lysis 
buffer (Thermo Scientific, Rockford, IL) containing protease inhibitors and vortexed. 
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The bacterial lysate was incubated for 10 min at 4 C with shaking on a tube rotator at 20 
rpm. The lysate was divided into 1 ml aliquots in screw-cap microfuge tubes, then 
centrifuged at 13,000 g for 20 min at 4 C. The supernatant containing the clarified 
BmAMA-1 ectodomain recombinant protein was transferred to screw-cap tubes and 
stored frozen until use. The pellets presumed to contain inclusion bodies as the fusion 
was not found in solution were also saved.   
His-Select Nickel Affinity gel suspension (100 µl) (Sigma, Aldrich, CA) was 
dispensed into a 2-ml microfuge tube, centrifuged for 30 sec at 5,000 g to pellet the 
resin. The supernatant was discarded and the resin was washed 2 times by centrifugation 
with 3 volumes of sterile deionised water, then equilibrated by the addition of 500 µl of 
equilibration buffer (QIAExpress, QIAGEN, Valencia, CA) in which it was 
resuspended. The resin was centrifuged for 30 sec at 5000 g, then the supernatant was 
removed and discarded.  
Purified BmAMA-1 recombinant protein 200 l at 5.52 g/µl prepared above 
was added to the equilibrated His-select nickel affinity gel resin and mixed on a tube 
rotator at 20 rpm for 1 hr at 4 C. After centrifugation at 5000 g for 30 sec, the fluid was 
removed by careful pipetting. The affinity gel was washed 2 times by centrifugation in 
1 ml wash buffer (QIAExpress Fast Start Kit, QIAGEN). The washes were saved as a 
pool for SDS-PAGE analysis. The bound protein was eluted 2 times with 50 l of elution 
buffer (QIAExpress Fast Start Kit, QIAGEN), with 5 min incubation with rotation at 20 
rpm at 4 C in the elution buffer prior to centrifugation as above.   
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A volume of 200 µl (28 g) of solubilized RBC proteins was mixed with the 
AMA-1 protein bound-resin from above and incubated overnight at 4 C with gentle 
rocking. After incubation the resin was allowed to settle, then the supernatant was 
removed. The resin was washed 3 times with 100 l of RIPA buffer (50 mm Tris pH7.2, 
150 mM NaCl, 5 mM EDTA, 0.1%SDS, 0.1% sodium deoxycholate, 1.0% Tween 20). 
The resin was allowed to settle at each wash and wash buffer removed by aspiration 
using a long pipette tip. Washes were saved as a pool for SDS-PAGE analysis. The 
resin-bound proteins were eluted with 50 µl of 100 mM glycine, pH 2.5 into tubes 
containing 10 l 1.0 M TRIS, pH 7.5. The protein concentration was determined by 
spectrophotometry as above and stored at –80 C in 10 l aliquots until use. 
The samples collected during immunoprecipitation were evaluated by SDS-
PAGE stained with Coomassie blue. The electrophoresed samples included human RBC 
membrane lysate (13.61 g), human RBC solubilized protein (14 g), purified 
recombinant BmAMA-1 protein (5.5 g), solubilized protein from transformed E. coli 
(5.5 g), presumed transformed E. coli inclusion bodies (4.66 g), elution of presumed 
RBC protein-AMA-1 complex (7.3 g), and a second elution of presumed RBC protein-
AMA-1 complex (5.1 g). 
Immunofluorescent binding assay 
 
BALB/C mouse blood collected in Alsever’s solution was washed 2 times in 5 
volumes of PBS containing 15 mM ethylenediaminetetraacetic acid (EDTA) followed by 
4 washes in PBS, with removal of the buffy coat at each wash. Washed RBCs were 
tested for auto-immunofluorescence prior and to non-specific binding and fluorescence 
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of Protein G-FITG. Five µl of Protein G-FITC conjugate was added to 1 µl of washed 
RBCs and incubated for 10 min with gentle rocking. The suspension was washed to 
remove unbound Protein G-FITC, then washed 3 times with 100 µl of PBS by 
centrifugation at 3,500 g for 3 min. After the last wash, the supernatant was removed and 
the pellet resuspended in 5 µl PBS. A sample of the RBC was viewed by UV 
microscopy to check for non-specific binding of the Protein G-FITC conjugate to the 
RBCs. 
Protein G binds to the FC portion of the leaving the binding site free (Sjobring et 
al., 1991). Mouse anti-His Moab will bind to the BmAMA-1 ectodomain fusion protein 
thus enabling the FC portion to interact with Protein G conjugated to FITC.  
For the immunofluorescence assay, 25 µl of purified BmAMA-1 ectodomain 
fusion protein at a concentration of 6µg/ml was added to 5 µl of  washed RBC and 
incubated under gentle mixing at 37 C for 1 and 2 hr. The RBC pellet was washed 3 
times with 300 µl PBS and the final pellet was incubated in 25 µl of mouse anti-His 
monoclonal antibody (Invitrogen, Carlsbad, CA) (diluted 1:5,000) for 30 min with gentle 
mixing at 37 C. The RBC were washed 3 times by centrifugation with 300 µl of PBS per 
wash. The final pellet was incubated with 25 µl of Protein G-FITC (Fluorescein  
isothiocyanate) conjugate diluted 1:10 in PBS for 30 min at 37 C with gentle mixing.  
After washing the RBC 3 times with 300 µl PBS, a sample was viewed by UV 
microscopy. Controls included RBC incubated with mouse anti-His monoclonal 
antibody and Protein G-FITC conjugate and RBC incubated with Protein G-FITC 
conjugate only. 
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RESULTS 
SDS-PAGE analysis of mouse, human, and horse RBC membrane preparations 
revealed by Coomassie blue staining showed 12 bands in the mouse (lane 2) of 
approximately 207, 114, 75, 64, 53, 49, 44, 35, 33, 30, 28, 6 kDa, whereas in the human 
there were 8 bands of approximately 207, 160, 114, 93, 53, 49, 44, 35 kDa. Horse RBC 
membrane protein preparations analyzed by SDS-PAGE and revealed by Coomassie 
blue produced 10 bands of approximately 207, 160, 137, 84, 56, 53, 49, 37, 28, 6 kDa 
(Fig. 17). Only bands of apparent molecular weights 207, 53 and 49 kDa were observed 
in RBC membrane preparations from all three species indicating possible conservation 
of these proteins.  
The detection of signal by far Western blot analysis of mouse RBC membrane 
proteins probed with BmAMA-1 ectodomain fusion protein indicated binding of the 
ligand which was detected by X-ray radiography. Validity of the interaction in each 
experiment was confirmed by testing for nonspecific binding of the primary antibody 
and the secondary antibody-conjugate to the RBC membrane proteins. BmAMA-1 
ectodomain fusion protein used in the interaction was included as a positive control. The 
results of the far Western blot analysis using mouse RBC membrane indicated 
interaction with the BmAMA-1 at approximate position 130 and 49 kDa (Fig.18). This 
interaction was observed in subsequent experiments indicating conserved binding of the 
BmAMA-1 ligands at this position to mouse RBC membrane proteins. The signal of this 
interaction was decreased when the RBC proteins were probed with a 2-fold decrease of 
the BmAMA-1 recombinant protein (Fig. 18).  
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Figure 17. SDS-PAGE of horse, human and mouse RBC membrane protein 
preparations. Lane 1, molecular weight marker. Lane 2, horse RBC; lane 3, human 
RBC; and lane 4, mouse RBC. Coomassie blue stain. 
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Figure 18.  Far Western blot of mouse RBC membrane proteins. Lanes 1 and 3,  
molecular weight marker. Lane 2, probed with 60 µg BmAMA-1 ectodomain fusion 
protein. Lane 4, probed with 30 µg BmAMA-1 ectodomain fusion protein. 
Chemiluminescence.  
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In far Western blot analysis of mouse and human RBC membrane proteins 
probed with BmAMA-1 ectodomain fusion protein, binding of BmAMA-1 ectodomain 
fusion protein was detected at approximately 207, 114, and 49 kDa for mouse RBC and 
at 207 and 49 kDa for human RBC (Fig. 19). The reaction at 130 kDa observed above 
with mouse RBC membrane proteins was not seen. 
 
 
                                 
 
 
 
 
 
In far Western blot analysis comparing mouse, human, and horse RBC 
membrane proteins probed with BmAMA-1 ectodomain fusion protein (Fig. 20), 
BmAMA-1 binding to mouse RBC membrane proteins was detected at approximately 
207, 56, 49, 37, 28 and 27 kDa, whereas binding to human RBC membrane protein was 
observed at 207, 114, 78, 56, 49 kDa. Thus BmAMA-1 fusion protein bound to RBC 
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Figure 19.  Far Western blot of mouse and human RBC membrane protein. Lane 1, 
human RBC. Lane 2, mouse RBC. Lane 3, BmAMA-1 ectodomain fusion protein. 
Probed with BmAMA-1 ectodomain fusion protein control. Chemiluminescence.   
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membrane proteins was conserved at position 207, 56 and 49 kDa. The 49 kDa position 
was also conserved in the horse which indicates inter species conservation of the 
receptor at this position. However, the binding signal at 49 kDa was stronger in the  
 
 
 
 
 
 
 
 
 
 
 
 
 mouse and human RBC protein compared to the horse, possibly indicating more 
specific binding of BmAMA-1 ectodomain fusion to the  mouse and human RBC 
membrane proteins. Subsequent far Western blots used more stringent washing to 
decrease the background observed in the previous experiments in analysis of binding of 
BmAMA-1 ectodomain fusion protein to mouse, human, or horse RBC membrane 
proteins. The BmAMA-1 binding to mouse RBC membrane proteins was detected at 
A     B 
     
Figure 20.  Comparison of horse, mouse and human RBC membrane proteins. (A) 
Coomassie blue stained SDS-PAGE and (B) far Western blot probed with BmAMA-1 
ectodomain protein Lane 1, molecular weight marker. Lane 2, mouse RBC. Lane 3, 
human RBC. Lane 4, horse RBC. Arrow indicates binding between BmAMA-1 and 49 
kDa RBC protein. 
  1            2            3 
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approximately 75, 64, 49 kDa positions, whereas with human RBC proteins, the binding 
signal was detected at 205, 114, and 49 kDa (Fig. 21). Binding to the horse RBC 
membrane proteins was observed at approximately 53, 49 and 28 kDa (Fig. 22). Only 
binding to the protein at position 49 kDa appeared to beconserved in the 3 species. 
Under more stringent wash condition, the marked difference in signal intensity among 
the three species was no longer observed.   
 
     A                B     
            
Figure 21.  Far Western blot analysis.  Mouse, horse and human RBC membrane 
protein probed with BmAMA-1 ectodomain protein. (A) Coomassie blue stained 
SDS-PAGE. Lane 1, molecular weight marker. Lanes 2, 3 and 4, mouse, horse, 
human and mouse RBC membrane protein, respectively. (B) Chemiluminescent 
far Western blot analysis. Lane 1, molecular weight  marker. Lanes 2, 3 and 5 
mouse, human and horse RBC membrane protein. 
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CHAPTER VI 
DISCUSSION AND CONCLUSIONS 
 
Babesia microti is a blood parasite that is transmitted by the tick Ixodes 
scapularis and is the most common cause of human babesiosis worldwide (Perry et al., 
1977; Dammin et al., 1981; Foppa et al., 2002). The vast majority of cases occur in the 
United States (Dammin et al., 1981; Borggraefe et al., 2006). There are no reliable tests 
that can be used to screen blood and organ donors in order to prevent transmission. 
There is no vaccine for the disease and side effects following drug treatment make 
therapy problematic (Homer et al., 2000; Krause, 2003; Gelfand and Vannier, 2005).  
Host cell invasion is a critical step in the pathogenesis of apicomplexan parasites  
including Babesia spp. (Mota et al., 2002; Krause, 2003; Lobo, 2005; Okamura et al.,  
2005). It is thought to involve a parasite ligand-host receptor interaction, which is  
supported by the following evidence. In vitro studies using Babesia bovis demonstrated  
binding ability of the merozoite RAP-1 to bovine erythrocyte lysate (Yokoyama et al., 
2002), which suggests interaction between this parasite ligand and the bovine 
erythrocyte. Antibodies to RAP-1 protein on the other hand significantly inhibit the 
proliferation of B. bovis in in vitro culture (Yokoyama et al., 2002), which suggests that 
these antibodies blocked the ligand partner of the cell receptors needed for interaction 
and invasion.  
Implication of apical membrane antigen 1 (AMA-1), another parasite ligand, in 
interaction with receptors on erythrocytes is evidenced by using antibodies to merozoite 
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AMA-1 to inhibit Plasmodium knowlesi invasion of erythrocytes in vitro (Thomas et al., 
1984). This again shows that the ligand on the merozoites is blocked by these antibodies 
preventing its interaction with host cell to enable invasion. Evidence of the interaction 
between ligand and cell receptors was also demonstrated in Toxoplasma gondii by 
depleting the tachyzoites of their AMA-1, which severely compromised their ability to 
invade the host cells. This data again provides evidence that there is interaction between 
this ligand and the host cell receptors which precede invasion of the cells (Adrian et al., 
2000; Mital et al., 2006). Also, complementation of the human malaria parasite 
Plasmodium falciparum AMA-1 with AMA-1 from the mouse parasite Plasmodium 
chabaudi allows P. falciparum to efficiently invade murine cells (Triglia et al., 2000), 
which also provides evidence that this ligand interacts with the host cell during invasion 
and that the interaction is species specific. Specific antibodies to B. bovis RAP-1 protein 
were used to inhibit sporozoite attachment to erythrocytes, indicating that these 
antibodies blocked the ligand that interacts with the host cell. Host cell invasion by 
Eimeria tenella sporozoites was completely inhibited by treating the sporozoites with 
proteases (Fuller and McDougald, 1990), which suggests that these proteases have 
hydrolyzed the proteins involved in interaction between the parasite and the 
erythrocytes. 
 The involvement of host cell receptors in parasite invasion has also been  
evidenced in vitro. First, pretreatment of the bovine erythrocytes with neuraminidase or 
trypsin, significantly decreases invasion by the parasite B. bovis and Babesia divergens 
(Zintl et al., 2002). This suggests that this treatment has removed the cell receptors that 
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could interact with the parasite to enable invasion. Babesia equi and Babesia caballi 
invasion of equine erythrocytes, on the other hand, was inhibited by treatment with 
neuraminidase, indicating again the involvement of cell surface receptors in invasion 
(Okamura et al., 2005). Erythrocytes deficient in glycophorin resist invasion by the 
malaria parasite P. falciparum (Pasvol et al., 1982), suggesting that the removal of this 
receptor from the host cell inhibits interaction with the parasite. Finally, surface proteins 
of P. falciparum merozoites bind to the erythrocyte receptor glycophorin and to products 
released by secretory organelles (Perkins, 1984), which indicates that P. falciparum 
merozoites interact with erythrocyte receptors and the proteins released from the apical 
organelles.  
These data suggest parasite ligand-host cell receptor interactions occur in 
invasion by apicomplexans. This also suggests that there is basic step in invasion 
consisting of an interaction between a parasite stage ligand and its receptor, which is 
followed by the internalization of the parasite. The process of invasion is mediated by 
proteins released from the organelles of the apical complex, shared by all apicomplexans 
(Dubremetz et al., 1998; Yokoyama et al., 2006) and the receptors on host cells 
(Mitchell et al., 1986; Lobo et al., 1991; Jones et al., 1992; Zintl, et al., 2002; 
Yokoyama, et al., 2006). Interacting parasite ligand-host cell receptors may vary as a 
result of the stage of the parasite involved in invasion and host cell types infected.    
The process of the entry of Babesia in host cell is likely similar to the entry 
described in other apicomplexan parasites, Plasmodium, Toxoplasma, Eimeria, and 
Isospora, because they are all mediated by an apical structure located in the apical 
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anterior end of these parasites. As indicated above, the type of cell infected may vary 
depending on the stage of the parasite involved in invasion. In Eimeria and Isospora, for 
instance, the oocyst excysts in the small intestine and the tachyzoites directly invade the 
cells lining the small intestine, which suggests that this stage of the parasite has the 
appropriate ligand to invade these cells. In Babesia, it is the sporozoite from the tick 
salivary glands that directly invades the erythrocytes (Jack and Ward, 1981; Igarashi et 
al., 1988; Krause, 2002), suggesting that this stage of the parasite has already developed 
the specific ligand to enter these cells. This is not seen in Plasmodium, where the 
sporozoite has to invade first the hepatocyte where it develops to merozoites which will 
in turn invade the erythrocytes.  
In the most studied parasite, Toxoplasma, the asexual stage tachyzoites move 
over the cell surface by an unusual form of substrate-dependent gliding motility, which 
brings the apical end of the parasite in contact with the host cell membrane. Apical 
secretory organelles (micronemes and rhoptries) then sequentially discharge their 
contents (Dubremetz et al., 1998; Carruthers and Sibley, 1997) and a zone of tight 
interaction forms between the parasite and the host cell (Dubremetz et al., 1998; 
Grimwood and Smith, 1996). An invagination in the host cell plasma membrane 
develops at the point of entry and progressively deepens, ultimately surrounding the 
fully internalized parasite (Suss-Toby et al., 1996). Only the slowly replicating forms of 
the parasite, the bradyzoites, are found within the parasitophorous vacuoles. These 
vacuoles form cysts in tissue to protect the parasite from the host immune system 
(Hutchison et al., 1969; Dubey, 1977; Dubey et al., 1998). This type of invasion is 
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similar to that described in Plasmodium (Jack and Ward, 1981), but in malaria two types 
of host cells are involved. As stated above, the sporozoite stage does not invade the 
erythrocytes directly, but travels to the liver and passes through several hepatocytes 
before establishing in one hepatocyte, then develops to merozoites (Mota et al., 2002). 
Merozoites then invade the erythrocytes and begin the asexual reproductive cycle (Jack 
and Ward, 1981). This suggests that the Plasmodium sporozoites are not able to directly 
invade the erythrocytes as do Babesia, which suggests that when coming from the 
mosquito, this stage does not carry the proper ligand to infect erythrocytes. Perhaps the 
Plasmodium interacting ligand for the erythrocytes needs processing in sporozoites when 
developing to merozoites in the hepatocytes. This also suggests that the receptor on the 
erythrocyte may be different from that found on the hepatocyte, which are easily invaded 
by the sporozoites. The sporozoites of Babesia, on the other hand, invade the 
erythrocytes directly and do not use any intermediary host cell (Jack and Ward, 1981), 
which suggests that sporozoites from the tick stage have already developed the proper 
ligand for directly entering the erythrocyte. In addition to this difference, there is no 
pigment formation in Babesia merozoites establishment while this is observed in 
Plasmodium, which suggests different requirements for establishing in the host 
erythrocytes.  
The difference between Babesia and Toxoplasma is that the tachyzoites reside 
within an intracellular vacuole and, following an unknown mechanism differentiates into 
encysted bradyzoites within host tissues (Dubey et al., 1998). These stages are not seen 
in Babesia where the sporozoites directly invade the host erythrocytes then reproduce by 
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asexual multiplication (Purnell, 1981; Taboada and Merchant, 1991; Homer et al., 2000).  
Toxoplasma and Plasmodium form a vacuole that is derived from the cell plasma 
membrane by an actin-myosin moving junction. But, the vacuole in Plasmodium does 
not form cyst as in Toxoplasma, and this stage is not found in Babesia (Jack and Ward, 
1981; Muller et al., 1993; Sharma et al., 1996; Soren et al., 2000). Another parasite 
ligand, TRAP (Thrombospondin Anonymous Protein), is thought to interact with 
skeletal proteins in gliding motility in malaria sporozoites and in Toxoplasma 
tachyzoites. This mechanism has not yet been described in Babesia (Sultan et al., 1997; 
Dubremetz et al., 1998).   
The roles played by proteins released from the apical complex of the parasite 
during erythrocyte invasion by some apicomplexan parasites such as Plasmodium and 
Toxoplasma have been investigated (Jack and Ward, 1981; Muller, 1993; Dalrymple et 
al., 1993; Collins et al., 1994; Denise et al., 1996; Adrian et al., 2000; Mota et al., 2002; 
Gaur et al., 2004). Proteins released from the rhoptries and micronemes have been 
shown to play a role in host cell invasion, but in most cases their precise functions 
remain incompletely understood (Dubremetz et al., 1998; Adrian et al., 2000; Gaur et al., 
2004; Yokoyama et al., 2006). Apical membrane antigen-1 (AMA-1) is one of these 
proteins that is secreted from the organelle microneme and has been shown to be critical 
for invasion. The precise function of AMA-1 is not well elucidated, but its role in host 
cell invasion is well documented (Triglia et al., 2000; Mota and Rodriguez, 2002; 
Yokoyama et al., 2006). AMA-1 homologues have been found in all apicomplexans 
studied to date (Triglia et al., 2000; Hodder et al., 2001; Silvie et al., 2004) and 
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characteristics such as the N-terminal ectoplasmic region, single transmembrane 
segment and small cytoplasmic domains are conserved. The AMA-1 molecule has 
remarkable conservation within and across genera (Waters et al., 1991; Denise et al., 
1996, Hodder et al., 2001). AMA-1 is stored in the microneme organelles after synthesis 
and is transported to the parasite surface just prior to, or during, host-cell invasion 
(Gaffar et al., 2004; Chesne-Seck et al., 2005).  
AMA-1 has been shown in P. falciparum and in B. bovis to inhibit host 
erythrocyte invasion by these parasites (Anders et al., 1998; Gaffar et al., 2004). 
Furthermore, T. gondii tachyzoites depleted of TgAMA-1 were severely compromised in 
their ability to invade host cells, providing direct genetic evidence that AMA-1 functions 
during invasion (Adrian et al., 2000; Mital et al., 2006). Also the specificity of protective 
antibody against AMA-1 has been documented in P. falciparum and was found in 
ectodomain portion of the ligand and was directed to conserved and strain-specific 
epitopes (Hodder et al., 2001). The presence of conserved epitopes in this domain and 
the ability of antibodies to this domain to inhibit parasite invasion suggests that it plays 
an important role in the process of invasion.  
Based on the above data, the ectodomain of B. microti AMA-1 was used in this  
study.  The full cDNA of the B. microti AMA-1 was previously prepared in the Dr. P.J. 
Holman laboratory by reverse transcription of mRNA obtained from U.S. isolate 
Peabody strain (Ruebush and Hanson, 1979). The B. microti full AMA-1 sequence 
possesses characteristics in common with AMA-1 from other apicomplexans, including 
a transmembrane domain, short cytoplasmic C-terminal, extracellular domain and 14 
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conserved cysteine residues. The complete nucleotide sequence of the B. microti ama-1 
gene is 1956 base pairs. The sequence contains an open reading frame of 1944 base pairs 
with a coding capacity of approximately 73 kDa (648 amino-acids) (Protein Calculator 
v3.3). The hydrophobic N-terminal, 42 amino-acids of B. microti AMA-1 were predicted 
to form a signal peptide (Signal P 3.0), whereas the hydrophobic stretch of 111 amino-
acids from Phe-1590-to Leu-1923  likely forms a transmembrane region, leaving a 11 
amino-acids as a cytoplasmic C-terminus (TMHMM 2.0).  
The ectodomain of the B. microti AMA-1 carrying 12 cysteine residues was used 
in this study instead of the entire B. microti ama-1 gene because, as previously indicated, 
the specificity of the protective antibody to the AMA-1 is located in this portion, and is 
directed to conserved and strain-specific epitopes (Hodder et al., 2001). In addition, this 
portion of the membrane bound polypeptide presumably extends into the  
extracellular space and likely interacts or initiates interaction with the host erythrocyte  
surface receptors.  
The 1474 base pair open reading frame of the B. microti AMA-1 ectodomain was 
amplified using specific primers designed from the 5  ´and 3 e´nds excluding the signal 
peptide and the transmembrane region of B. microti ama-1 gene. These two domains 
were removed because the first attempts to express AMA-1 sequence carrying these 
regions were not successful. Generally, expression of recombinant proteins carrying 
hydrophobic regions, such as the signal peptide and the transmembrane domain, often 
have a toxic effect on the host cell which blocks expression. This is most likely due to 
the association of the protein with toxic products and the incorporation of these products 
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into vital membrane systems (Waeber et al., 1993). For the various known signal 
peptides, there is no consensus sequence in the primary structure, but they share 
common structural features consisting of three distinct regions: the basic region, the 
hydrophobic region, and the cleavage region (Goldstein et al., 1990). Signal peptide 
hydrophobicity appears to be more critical for the efficiency of early stages in protein 
expression and export (Goldstein et al., 1990). A hydropathic plot of B. microti  
AMA-1 amino acid sequence showed 3 hydrophobic domains in the transmembrane 
region (TMHMM 2.0). Based on the data above and the potential toxic effect of 
hydrophobic domains on expression, the sequences coding for the signal peptide and the 
transmembrane domain were removed from the B. microti ama-1 gene sequence.  
The ectodomain region was amplified from the full B. microti ama-1gene 
sequence using specific primers internal to the signal peptide and the transmembrane 
region. The ectodomain was ligated into the pET TOPO 101D vector, which produces a 
fusion protein with a V5 epitope and 6x His tag at the C-terminus. Vectors that place the 
His-tag at the C-terminus are recommended for open reading frames which may result in 
premature translation termination (Fry and Loeb, 1992) and to ensure that only full-
length proteins are purified. The features of the pET TOPO 101D plasmid, such as T7lac 
promoter, IPTG-inducible expression of the gene in E. coli, C-terminal fusion tags for 
detection and purification of recombinant fusion, pBR322 origin for stringent replication 
and maintenance in E. coli of the lacI gene that reduces basal transcription from the 
T7lac promoter make this plasmid an excellent choice for this study. Use of pBR322 
origin for stringent replication is important because high copy number (relaxed 
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plasmids) allows maximum gene expression, but the metabolic burden effects resulting 
from multiple plasmid copies could be detrimental to expression (Jones et al., 2000). 
An advantage of the pET TOPO101 D was that the primer design allowed 
directional ligation of the B. microti ectodomain gene sequence in this vector. PCR 
products were generated using a high fidelity DNA polymerase (Phusion, New England 
BioLabs, Ipswich, MA). The choice of the polymerase is important because the 
specificity of the interaction between the ectodomain and the receptors on the host cell 
will depend on the correct sequence of the residues in each binding partner and may be 
linked to a single or few residiues in the ectodomain. This particular polymerase has a 
strong proofreading activity and a processivity-enhancing domain. Its error rate is 
approximately 50-fold lower than that of Taq polymerase (New England BioLabs). This 
polymerase amplifies with an extreme fidelity and possesses a 5 ´3  ´DNA polymerase 
activity and 3 ´5  ´exonuclease activity. Denaturation and annealing were carried out at 
elevated temperatures, thus increasing the specificity of the amplification. This 
characteristic makes this polymerase a good choice for this study. But, the pitfall in 
ligating the insert in this vector is that the percentage yield for suitable plasmid was very 
low. Only one clone out of seven (15%) was found with proper orientation with no 
internal stop codon. All the clones sequenced had the insert. However, internal stop 
codons were found in all except one probably due to mis-incorporation or deletion of 
nucleotide during gene amplification which resulted in translational frameshifting 
(Farabaugh, 1996).  This may be due to polymerase inaccuracy during amplification 
which causes nucletotides to be incorporated or deleted from the sequence. In order to 
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correct this pitfall and increase our chance of getting more clones with correct sequence 
and no internal stop codons, a polymerase having a tight control of polymerase-catalyzed 
DNA extension with very low probability of base mis-incorporation should be used to 
amplify the B. microti ectodomain fusion protein. Isis DNA polymerase (MP 
Biomedicals, Solon, OH) shows this advantage with a rate of one base per 1600 
molecules of 1.0 kb DNA per PCR cycle. This polymerase has also a very robust activity 
and requires less time for reaction set-up and optimization, which will decrease base 
deletion or mis-incorporation. This polymerase is recommended for PCR applications 
requiring very low probability of base mis-incorporation (MP Biomedicals, Solon, OH ).
Even though this polymerase has a lower proofreading capacity (error rate 40-fold lower 
than Taq) than the Phusion High Fidelity Polymerase, the features cited above make it a 
good choice for amplifying B. microti AMA-1 ectodomain fusion protein.    
For expressing B. microti AMA-1 ectodomain fusion protein, BL21 E. coli strain 
(Invitrogen, Carlsbad, CA) was used. This strain was selected because of previous 
reported success in expressing B. bovis apical membrane antigen-1 (Gaffar et al., 2004). 
BL 21 E. coli lacks two key proteases lon protease and OmpT, which reduce degradation 
of heterologous proteins expressed in this strain (Invitrogen, Carlsbad, CA). Babesia 
microti AMA-1 ectodomain fusion proteins were obtained with molecular mass of 58.1 
kDa for fusion protein as expected, with 4 kDa accounting for the vector sequence 
including the 6x His tag. However, the pitfall of using this strain is that expression was 
not reproducible using clones from the same batch of cultures which suggests clonal 
variation in ability to express the protein. This may be caused by clones losing the 
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expression plasmid or the plasmid losing the insert during the transformation or 
expression process. It may also be due to low level of expressed protein, which may not 
be detectable by our analysis methods. In order to prevent the loss of expression plasmid 
resulting from non-selective conditions and to increase expression levels, carbenicillin 
was used in selective media as suggested by the manufacturer. Carbenicillin is generally 
more stable than ampicillin, and studies have shown that using carbenicillin in place of 
ampicillin may help to increase expression levels by preventing loss of the pET TOPO® 
plasmid (Invitrogen, Carlsbad, CA). However, the use of carbenicillin in place of 
ampicillin did not correct this problem in our expression.  
The low expression in this strain could also be attributed to stalling of 
expression, possibly due to depletion of specific tRNAs not found in many prokaryotic 
expression systems. This occurs especially when expressing proteins from AT or GC 
rich genomes of protozoan origin like Babesia spp. (Marshall et al., 1989; Flick et al., 
2004; Kirsten et al., 2004). Analysis of the B. microti AMA-1 ectodomain sequence 
showed 58% AT (mbcf.dfci.Harvard.edu/docs/oligocalc.htm) which is low when 
compared to over 69 to 70% for Plasmodium spp. (Marshall et al., 1989). In order to 
correct potential codon bias in expressing the B. microti AMA-1 ectodomain we selected 
BL21 Codon Plus. This strain contains extra copies of specific tRNAs for ile, leu, pro 
and arg (Stratagene, La Jolla, CA). Availability of these tRNAs may allow high-level 
expression of many heterologous recombinant proteins not highly expressed in other 
E. coli strains. The BL21 codon Plus strain was successfully used to express malaria 
AMA-1 gene (Flick et al., 2004). Therefore, it was reasoned that using this strain may 
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correct potential codon bias that might stall the expression of our protein. The B. microti 
ectodomain possesses 7, 2, 4, 6 and 5 residues corresponding to the rare ile, leu, pro and 
arg tRNAS provided by this strain. Thus, the requirement for these particular tRNAs is 
relatively low in the B.  microti AMA-1 ectodomain protein sequence for constituting a 
potential problem for expression. Another advantage in using this strain is that 
chloramphenicol is required in the medium to maintain plasmid stability in the cell in 
addition to the selective marker carbenicillin which also prevents the loss of the plasmid. 
Thus, plasmid stability in this strain is reinforced by the use of chloramphenicol in 
addition to the carbenicillin in the bacterial culture medium. 
Babesia microti AMA-1 ectodomain was successfully expressed in the BL21 
Codon Plus strain and the expression was reproducible. However, the concentration of 
protein yielded was less (0.29 ug/ul) than what was achieved in BL21 Star DE3 (0.83 
ug/ul), suggesting that the low level or lack of expressed protein in certain clones of 
BL21 Star DE3 was not a result of stalling due to lack or depletion of certain tRNAs 
pool, but probably to other components in the expression process. For instance, growth 
inhibition due to toxic products released by the cells or cessation of plasmid-bearing 
cells after induction could well result in no yield or reduced yield. Changes in expression 
capacity of certain cells have been documented and were attributed to metabolic burden 
or toxicity caused by the overexpression of the target gene or to loss of the expression 
plasmid (Zhao and Wei, 2007). In our specific case, only the loss of the expression 
plasmid can be suspected using BL21 Star DE3 because the expression was done 
successfully using some clones. This suggests that the clone which did not express our 
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protein may have lost the plasmid when growing on agar plate or during cell growth in 
Luria Bertani (LB) medium.   
Expressed recombinant BmAMA-1 fusion protein was analyzed by SDS-PAGE 
gel stained with Coomassie blue (BIO-RAD, Hercules, CA), then by Western blot 
analysis. Although Coomassie blue detects 50-fold less protein (30-100 ng) than silver 
stain (1 ng), we were able to detect our protein using this stain and monitor the timeline 
signal of our desired 58.1 kDa protein. However, silver stain should be used in future 
expression experiments to assess the efficiency of our purification process. This will 
help determined the number of non-specific bands (or contaminants) at the nanogram 
level that might not react in Western blot analysis.  
Enrichment of the B. mciroti AMA-1 recombinant protein under native 
conditions was not successful as the protein was found in the lysate flow-through, which 
indicates that the protein did not bind to the nickel column, or did not carry the His tag to 
allow it to bind. This suggests that the protein extraction method did not result in protein 
that was in a form that could bind to the affinity column. In general, heterologous protein 
expression in E. coli most often leads to the protein being expressed in insoluble forms 
known as inclusion bodies. The tag of the protein likely is partially hidden in these forms 
(Bowden and Gergiou, 1990; Thomas and Baneyx, 1996; Chumpia et al., 2003). Under 
denaturing conditions, the tag will be exposed to allow binding to the Ni-NTA (Nickel-
Nitrilotriacetic Acid) matrix (Thomas and Baneyx, 1996).  
Based on the results outlined above, affinity enrichment was used under 
denaturing conditions, which produced fusion protein that was visualized using SDS-
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PAGE stained with Coomassie blue and by Western blot analysis. Ni-NTA Spin Column 
(QIAGEN, Valencia, CA) was used for rapid screening and enrichment of the 6x His- 
tagged B. microti AMA-1 ectodomain proteins from 50-ml cultures. When eluted fusion 
proteins were analyzed on SDS-PAGE stained with Coomassie blue and in Western blot 
one to six bands between 58 kDa and 23 kDa were observed. The extra bands could be 
other histidine rich protein or possibly breakdown products of the B. microti AMA-1 
ectodomain fusion protein. Since protease inhibitors were not added to these elutions, 
these bands, or some of these bands, could well be breakdown products of the fusion 
protein. 
The failure of the native purification and the success in enrichment under 
denaturing conditions suggest that the His-tag on the fusion protein was not exposed 
under native conditions and that denaturing agents exposed the histidine residues 
allowing interaction with the nickel ions on the column.  
The microspin nickel affinity resin used for rapid screening and enrichment of 
the expressed protein accommodates only 600 µl of cleared cell lysate derived from a 
50-ml culture. The column is centrifuged immediately after loading the cleared 
supernatant containing the fusion protein, which does not give much time for the fusion 
protein histidine residues to interact with the nickel resin. This might explain the low 
yield after enrichment as revealed by low signal of bands following staining with 
Coomassie blue and in Western blot using anti-His antibody.  
Downstream applications are focused specifically on epitope interactions 
between the fusion protein and the host cell receptors, and raising antibody against the 
  
  76 
fusion protein to use in invasion inhibition and other assays. Enrichment of recombinant 
proteins under native conditions is generally preferred, but if proteins are to be used for 
antibody production there often is no need for native enrichment or renaturation 
(Wingfield et al., 1995; Von Specht et al., 2000). Downstream applications such as 
examining protein interactions and antibody production are epitope-based assays, 
therefore native enrichment is not critical for these interactions. However, proper 
controls should be set in each experiment to determine the validity of the results.  
Enrichment of B. microti AMA-1 recombinant protein from large scale cultures 
was achieved using a gravity-driven nickel affinity column (FAST START, QIAGEN, 
Valencia, CA) under denaturing conditions. To increase the yield, the cell pellet was 
frozen and thawed three times in liquid nitrogen to free the recombinant protein. 
Protease inhibitors were added before the pellets were thawed for the first time to 
prevent degradation of the protein. SDS-PAGE and Western blot analysis of the 
subsequently enriched proteins revealed almost no recombinant protein in the clear 
lysate flow-through indicating binding of the target protein to the capture resin. 
Including freeze/thaw cycles increased the binding of the BmAMA-1 protein and, 
therefore, the efficiency of the enrichment. There were 3 to 4 bands between 58 kDa and 
30 kDa observed on SDS-PAGE and Western blot following the enrichment by this 
method, with eluted protein concentrations from 0.28 µg/µl to 0.83 µg/µl for all 
enrichments using this method. The gravity-driven affinity column holds up to 10 ml of 
cleared cell lysate. Pellets from 250 ml-culture were used to increase the concentration 
of the eluted protein to get the best yield.  This procedure gives more time for the His tag 
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to interact with the nickel ions that could lead to more affinity binding and more eluted 
fusion protein. These B. microti eluted fusion proteins were used in downstream 
applications (far Western blot, immunoprecipitation, and immunofluorescent binding 
assays).  
To produce B. microti AMA-1 ectodomain fusion protein in high concentration 
for other applications using these methods, a large volume of the cleared cell lysate 
supernatant must be enriched because microgram amounts will be needed for antibody 
production and in vivo immunization assays, for example. Five to 10 liters of bacterial 
culture should be processed and enriched under denaturing conditions using bigger 
affinity purification columns. This large volume could yield 22 to 44 g of B. microti 
fusion protein considering the lowest yield 0.28 g/l (in approximately 1 ml elution) 
under the conditions cited here.   
Interaction of B. microti AMA-1 ectodomain with host red blood cell membrane 
proteins was investigated. Enriched recombinant B. microti AMA-1 showed bioactivity 
in far Western blot analysis using mouse, human, or horse RBC membrane protein. 
Interaction with a protein at position 49 kDa was observed when RBC membrane 
proteins from the mouse, human and horse were reacted with B. microti AMA-1 
ectodomain protein. This band was consistent in all experiments. The specificity of the 
binding was confirmed by testing potential binding of the primary and secondary 
antibodies to the RBC membrane proteins.  
The signal of binding at 49 kDa observed with the horse RBC appears to be less 
than with mouse and human RBC membrane proteins, possibly indicating less 
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specificity of B. microti AMA-1 ectodomain fusion protein for the horse RBC. The 
relatively higher signal observed in mouse and human suggests more specific binding of 
the protein for the RBC proteins of these species, which are known hosts for this 
parasite. However, this difference in the binding signal was not consistently observed in 
subsequent experiments using interaction with the same erythrocyte membrane proteins, 
especially under more stringent wash conditions. The non-reproducibility of the results 
under different experimental conditions suggests that alternatives should be tested, such 
as using specific anti-BmAMA-1 antibody instead of anti-His antibody for detecting the 
interaction with the RBC membrane proteins.  The current results suggest that the 
difference in the intensity of the interacting signal observed at 49 kDa may not be linked 
to the susceptibility of the host to this parasite, but more likely to the nature of the RBC 
receptor involved in interaction.  It is also possible that the binding observed is not 
BmAMA-1 binding to the RBC protein, but rather one of the multiple bands found in the 
enriched protein.  Using a specific antibody would determine if BmAMA-1 is binding to 
the 49 kDa protein. Therefore, further investigations are needed to confirm that the 
B. microti AMA-1 ectodomain fusion protein binds at this position.  Once confirmed, 
then further investigation also is needed to assess the composition of the binding partner, 
the 49 kDa RBC membrane protein, as discussed below. . 
Further work will require more BmAMA-1 recombinant protein of high quality 
and specific antibody to this protein.  Large volumes of culture (4-6 liters to yield 
approximately 4-8 g of protein considering a lowest yield of 0.28 g/µl from 250-ml 
cultures) should be grown and processed to purify the B. microti AMA-1 ectodomain 
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fusion protein. The fusion protein will be enriched from the cleared supernatant using 
anti-V5 antibody (Southern et al., 1991) coupled to magnetic beads for more specific 
binding of the protein to the capture matrix.  The capture antibody must react 
specifically with our B. microti AMA-1 ectodomain fusion protein, thus using antibody 
to the V5 epitope will minimize the non-specific capture of histidine-rich contaminants 
observed using His-tag affinity enrichment. Unbound proteins will be washed away then 
the fusion protein will be eluted in solution containing protease inhibitors. Samples will 
be processed by SDS-PAGE and protein bands will be revealed by silver staining to 
assess the level of enrichment and by Western blot analysis using both anti-His antibody 
and anti-V5 antibody. If there are extra bands observed in using silver staining and 
Western blot using His-tag this confirms the presence of histidine-rich proteins which 
are not breakdown products of the fusion proteins stated earlier. Therefore, affinity 
enrichment using nickel column may need to be followed by another methods such as 
V5 antibody or specific BmAMA-1 antibody affinity purification to obtain highly 
purified BmAMA-1 recombinat protein for use downstream applications.  The quality of 
the protein purified by this method will be determined by SDS-PAGE stained with silver 
stain and by Western blot analysis, and the concentration determined.  Antibodies to 
highly purified fusion protein will be raised in rabbits.  
To show interaction between the 49 kDa RBC membrane protein and BmAMA-
1, purified B. microti AMA-1 ectodomain fusion protein obtained above will be 
electrophoresed on SDS-PAGE as previously described, then transferred to 
nitrocellulose membrane. Membranes carrying the B. microti AMA-1 ectodomain fusion 
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protein will be incubated with erythrocyte membrane proteins (mouse, human and 
horse). Unbound membrane proteins will be washed away and the membranes probed 
with anti-V5 antibody tagged with horseradish peroxidase, or another enzyme, then 
reacted with the substrate to detect binding. There should be no reaction at the 49 kDa 
position, indicating that the erythrocyte membrane proteins bound to the protein at this 
position and prevented the AMA-1 antibody from binding. Controls will include reacting 
anti-V5 antibody directly with the fusion protein on the membrane. 
Another experiment to confirm binding of B. microti AMA-1 ectodomain fusion 
protein at the 49 kDa band position will be done using far Western blot analysis.  
Erythrocyte membrane proteins from mouse, human, and horse will be separated by 
SDS-PAGE in two gels and transferred to nitrocellulose membranes for far Western blot 
assays. The first membrane will be probed with B. microti AMA-1 ectodomain fusion 
protein with the V5 epitope, whereas the second membrane will be probed with an 
irrelevant protein also carrying a V5 epitope. Binding of the two proteins at 49 kDa 
position will be determined by anti-V5 antibody tagged with horseradish peroxidase or 
with fluorescein for detection. There should be no interacting band at position 49 kDa on 
the membrane probed with the irrelevant protein, indicating that the irrelevant protein 
did not bind at this position, whereas the band at position 49 kDa should be detected on 
the membrane probed with BmAMA-1, showing that the B. microti AMA-1 ectodomain 
fusion protein bound to that RBC protein. Controls should include anti-V5 antibody that 
will be reacted with the erythrocyte membrane proteins and B. microti AMA-1 
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ectodomain fusion protein that will be reacted with the anti-V5 antibody. Results from  
this experiment will determine binding of B. microti AMA-1 ectodomain at this position. 
The next experiment will be to elucidate the B. microti AMA-1 erythrocyte 
binding partner(s) by far Western blot analysis and mass spectrometry analysis of the 
interacting band at 49 kDa position. Erythrocytes membrane proteins from mouse, 
human and horse will be separated by SDS-PAGE in duplicate gels.  One gel will be 
stained with silver stain and the other will be analyzed by far Western blotting to 
confirm binding of BmAMA-1 with the protein at 49 kDa.  The RBC proteins that show 
binding with the BmAMA-1 protein will be further analyzed by mass spectrometry and 
Edmann amino acid sequencing. Analysis of the amino-acid composition of these bands 
in B. microti susceptible and in non-susceptible host erythrocytes may provide insight in 
the amino-acids residues involved in interaction.  
The sialic-acid rich residues of the erythrocyte receptors (glycophorin) have been 
implicated as receptors for AMA-1 in many apicomplexans (Pasvol et al., 1982; Perkins 
et al., 1984; Heinz, 1978; Zintl et al., 2002; Gaffar et al., 2003; Gaur et al., 2004; Lobo, 
2005; Okamura et al., 2005). Glycophorin implication as erythrocyte receptors in cell 
invasion by B. equi and B. caballi has been investigated (Murayma et al., 1981; 
Okamura  et al., 2005). Dimers and monomers of glycophorin in terms of their molecular 
weights and sialic acid-rich nature were then removed by neuraminidase treatments. In 
vitro growth of both parasites was influenced by the removal of sialic acids from the 
surface of equine erythrocytes, suggesting that glycophorin interacts with the parasites to 
allow invasion by B. caballi and B. equi. Babesia divergens invasion of bovine 
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erythrocytes was also inhibited by neuraminidase treatment, suggesting that the sialic 
acid-rich residues (glycophorin) are the interacting partner of the parasite on the surface 
of the cells (Zintl et al., 2002). Babesia bovis merozoites were shown to invade human, 
ovine, porcine and caprine erythrocytes by sialic acid dependent mechanisms (Gaffar et 
al., 2003), indicating these parasites interact with these receptors to enable them to 
invade the cell.  
Furthermore, Plasmodium spp. merozoites and products released by secretory 
organelles were shown to bind to glycophorin (Perkins, 1984). Erythrocytes deficient in 
glycophorin resisted invasion by P. falciparum, indicating that this parasite and its 
released products bind to this receptor and that removal of this receptor prevents 
invasion by this parasite. Finally, it has been shown that Babesia and Plasmodium use 
common receptors, glycophorin A and B, to invade host erythrocytes (Lobo, 2005), 
which suggests that the role of this receptor in cell invasion is shared by different genera 
in the phylum apicomplexan.   
The findings described above indicate that current knowledge targets the sialic 
acid-rich residues of glycophorin as the erythrocyte receptor involved in invasion by 
both Babesia and Plasmodium. But, as yet the detailed knowledge of these residues and 
the structure of the ligand or part of the ligand that binds to them remain incompletely 
understood (Dubremetz et al., 1998; Gaur et al., 2004; Triglia et al., 2000; Yokoyama et 
al., 2006). For B. microti AMA-1 ectodomain fusion protein, further studies are needed 
to determine if the band at position 49 kDa is first sialic acid-rich (glycophorin) and then 
determine the structural composition of this band. Potentially, this will enable not just 
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identification of the receptor structures required for invasion by B. microti, but 
potentially could be used to identify potential susceptible hosts for this parasite by just 
comparing the amino-acid composition of their erythrocyte receptors to those of   
susceptible hosts (mouse, human).   
Far Western blot analysis in the current study indicates binding of B. microti 
AMA-1 ectodomain fusion protein to horse erythrocyte membrane proteins as well as to 
mouse and human, suggesting that the interacting receptors on these erythrocytes may 
share similar structures. It is possible that these receptors are the sialic acid-rich residues 
present on the erythrocytes of these three species, as demonstrated for other 
apicomplexans, since erythrocytes from all species possess sialic acid-rich reidues 
(glycophorin) (Pasvol, 1982; Perkins, 1984; Zintl et al., 2002; Okamura et al., 2005). 
However, other residues like those suspected in sialic acid independent pathway might 
be involved (Lobo et al., 1991; Yokoyama et al., 2006). Additional experiments will be 
needed to further confirm the involvement of these receptors in invasion by B. microti.  
The role played by glycophorin as a receptor in invasion by B. microti may be 
investigated using in vitro assays and in vivo assays. In vitro assays might include 
enzyme treatment of erythrocytes, blocking the putative receptor with anti-glycophorin 
antibody, and far Western blot analysis testing binding of BmAMA-1 to membrane 
proteins from normal erthryrocytes and from glycophorin deficient erythrocytes.  In vivo 
assays might use infection studies of transgenic mice or hamsters deficient in 
glycophorin compared to normal controls. 
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Babesia microti AMA-1 binding to mouse, human and horse erythrocytes treated 
by neuraminidase could be evaluated based on the discussion above (Pasvol et al., 1982; 
Zintl et al., 2002; Lobo et al., 2005). Briefly, erythrocytes from mouse, human, and 
horse will be washed with PBS then incubated in neuraminidase solution. Incubated 
erythrocytes will be washed in PBS containing non ionic detergents, then erythrocyte 
membrane proteins will be prepared as previously described. Far Western blot assays 
will be done as previously described. Treated and non-treated erythrocyte membrane 
proteins will be separated by SDS-PAGE, transferred to nitrocellulose, then probed with 
B.microti AMA-1 ectodomain fusion protein. Anti-V5 antibody labeled with an enzyme 
or with fluorescein will be used to detect binding. Non-treated erythrocyte membrane 
proteins will be used as controls. Controls will also include probing the RBC proteins 
with anti-V5 antibody alone. Expected results will be no signal between the treated RBC 
protein and BmAMA-1, which would suggest that glycophorin is involved in the 
interaction between B. microti AMA-1 and the host erythrocyte. Signal may be observed 
if treatment with neuraminidase is not complete, meaning all sialic residues were not 
removed during treatment. Signal may also occur if glycophorin is not the erythrocyte 
receptor for BmAMA-1.  Using more concentration of neuraminidase or longer 
incubation in neuraminidase followed by stringent washing could be used to test for 
binding to residual sialic acid.   
Anti-glycophorin antibody that binds to the erythrocyte membrane proteins to 
prevent binding of B. microti AMA-1 ectodomain fusion protein might be used in a far 
Western assay. Electrotransferred erythrocyte membrane proteins will be incubated with 
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anti-glycophorin antibody then reacted with recombinant BmAMA-1 fusion protein. 
Controls will include erythrocyte membrane proteins probed with B. microti AMA-1 
ectodomain fusion protein as a positive control, and the V5 antibody that will bind 
directly to the erythrocyte membrane proteins. Absence or very low signal at position 
49 kDa in the reaction compared to the positive control signal, would suggest that anti-
glycophorin antibody prevented binding of B.microti AMA-1 ectodomain fusion protein. 
This might indicate that glycophorin is an interacting partner for B. microti.  
Offspring of transgenic mice or hamsters produced by knocking out a gene that 
codes for glycophorin or by disrupting this gene could be assessed for infectivity by 
B. microti. The following generation of mice or hamsters deficient in glycophorin on 
their erythrocytes would be challenged by inoculating them with B. microti infected 
blood. Controls would include normal animals challenged with the same dose as the 
transgenics. The parasitemias would be monitored daily to determine infection. The level 
of parasitemias in test animals when compared to the controls would indicate that 
glycophorin acts or does not act as a receptor in invasion by B. microti.    
Future studies will be focused on elucidating the structure of the interacting 
partner of B. microti AMA-1 and the 49 kDa mouse, human and horse erythrocyte  
membrane proteins. For erythrocyte receptor involvement in invasion, sialic acid- 
dependent and sialic acid-independent interactions (Mitchell et al., 1986; Lobo et al., 
1991; Lobo, 2005) must be investigated to determine the impact of each in the invasion 
process by this parasite. This will indicate if in interaction is restricted to glycophorin or 
if other interacting partners are involved.  
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Ideally, in order to investigate the role played by transmembrane proteins (sialic 
independent pathway) erythrocytes will be treated with neuraminidsae and then trypsin 
respectively and assayed for invasion in vitro. However, at present there is no in vitro 
culture system for B. microti. Further reduction of invasion by these two treatments 
when compared to treatment by neuraminidase only would suggest that the receptor role 
is not restricted to glycophorin only and that an alternative pathway may be involved.  
Studies should also include additional in vivo invasion inhibition assays. These 
might include passive transfer of anti-B. microti AMA-1 antibodies to mice or hamsters 
as described in infection studies for other apicomplexans. Then, mice or hamsters would 
be challenged with B. microti infected blood (Thomas et al., 1984). Controls would 
include mice and hamsters that receive no anti-B. microti AMA-1 antibodies. 
Parasitemia in test and control animals would be monitored daily and compared on a 
plot. Low, static, or no parasitemia would indicate protection conferred by anti- B. 
microti AMA-1 antibodies.  
Protection from infection after inoculating mice or hamsters with the 
recombinant B. microti AMA-1 ectodomain fusion protein might be assayed as 
described in similar experiments for Plasmodium spp. (Deans et al, 1984; Collins et al., 
1994; Anders et al 2005). The V5 epitope and the His-tag would be removed from the 
recombinant protein before immunization. Test mice or hamsters will be immunized 
with B. microti AMA-1 ectodomain protein in Freund’s Adjuvant (complete, 
incomplete). The resulting antibody level would be be measured by Enzyme Linked 
Immunosorbant assay (ELISA) until it reaches a plateau. Controls would include mice or 
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hamsters that receive only the adjuvant. The animals would be challenged with the same 
dose of B. microti infected blood after the antibody plateaus. Parasitemias in test animals 
and in controls after challenge would be evaluated daily and analysed on a plot. If the 
immunized animals do not develop a parasitemia or if they develop a low parasitemia 
compared to the controls, this would indicate that immunization with B. microti AMA-1 
ectodomain protein inhibits erythrocyte invasion in vivo, which would suggests a 
protective role by this portion of the B. microti AMA-1 ligand. Studies may also include 
in vitro cross invasion inhibition assays and cross protection studies using B. divergens.     
Finally, an important inference in the interaction between B. microti AMA-1 
ectodomain fusion protein and the receptors on the erythrocytes membrane could be the 
transmembrane domain of the B. microti AMA-1. This domain could have a profound 
effect on the stability of interaction.Therefore, a hydropathic plot of B. microti AMA-1 
was constructed using TMHMM 2.0 (Fig. 22). Analysis of this plot showed three 
hydrophobic domains represented by residues 20-42, 531-553 and 616-638 and four 
hydrophilic domain residues 1-19, 43-530, 554-6145 and 639-649.  
The hydrophobic domain of the protein resides only in the lipid bilayer core of 
the membrane, while hydrophilic domains protrude into the watery environment inside 
and outside the cell. The lipid environment provided by the transmembrane domain 
could affect the stability of interaction as a result of signal transduction through 
hydrophobic or hydrophilic interactions between the erythrocytes and this domain. The 
impact of this domain on the stability of the interaction might be investigated by 
expressing the B. microti AMA-1 protein with this domain and probing RBC membrane 
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Figure 22. Hydropathic plot of B. microti AMA-1. TMHMM 2.0 (CBS;  
Denmark). Len=649, ExpAA=66.61, First 60= 22.51, PredHel=3.   
 
proteins in far Western blot assays. Because of its hydrophobic nature, other expression 
systems such as yeast or mammalian cells may be better used to express this domain.    
In summary, invasion of host cells by apicomplexans is likely a multi-step process 
which involves proteins released from the rhoptries and the micronemes and possibly two 
types of receptors (sialic-acids and proteins) on the host cells. The role played by both the 
parasite ligands and the receptors on the host cells are not yet well understood. However, 
data obtained so far target three ligand proteins, RAP, AMA-1 
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and TRAP, from the parasite apical complex, which appear to be involved in invasion. 
However, the involvement of these ligands during invasion may vary depending on the 
parasite stage and cell type. Among these ligands, based on the information to date, 
AMA-1 appears to be the most critical in invasion.  
Cell surface receptor partners involved in invasion have also been investigated, 
especially the receptors on erythrocytes. Data obtained so far suggest that glycophorin is 
the main interacting receptor partner on these cells. However, an alternative pathway of 
invasion has been described (Lobo et al., 2003) called the sialic-independent pathway. 
Further investigation is needed to study the roles played by these two pathways in 
Babesia invasion of the host erythrocyte and to determine the structures of the receptors 
and the structures of the ligands involved in the host-parasite interaction. 
In conclusion, this study provides a new approach in investigating the role played 
by B.microti AMA-1 in erythrocytes invasion by this parasite. A specifc domain   
(ectodomain) of this ligand (AMA-1) was used to investigate this role. Results obtained 
suggest that there is interaction between B. microti AMA-1 and a 49 kDa host red blod 
cell protein and suggest that an erythrocyte membrane protein of 49 kDa is likely to be 
involved in invasion by B. microti. However, further investigation is needed.  Studies 
aimed at elucidating the structure of the host cell receptor(s) at this position and the 
structure of the interacting parasite ligands should also be investigated to bring more 
insight to the invasion process of B. microti. Information from such studies will pave the 
way to developing better therapeutics and vaccines to counter the disease caused by this 
parasite. 
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